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ABSTRACT 
Electrochemical-based biosensors offer relative facile fabrication procedures, label 
free operation and rapid in field sensing and may hold a key to point-of-care diagnosis. 
Interdigitated electrodes (IDE) are often employed as the main sensing platform, and they 
consist of alternating ‘finger-like’ electrodes that are electrically connected with a width 
and pitch typically in the range of 5 – 25 m. Through the sensing modality of 
electrochemical impedance spectroscopy (EIS), it reveals small variations in 
resistance/capacitance due to the binding of biological recognition agents and biological 
targets. This dissertation documents the innovative research in electrochemical biomarker 
detection with interdigitated electrode arrays that I have been working on throughout my 
PhD training at Iowa State University. 
A label-free EIS aptasensor for rapid detection of interferon-gamma (IFN-γ) was 
fabricated by immobilizing a RNA aptamer capture probe, selective to IFN-γ, on a gold 
IDE. The Au IDE functionalized with a surface ternary monolayer was able to measure 
IFN-γ in actual fetal bovine serum with a linear sensing range from 22.22 pM to 0.11 nM 
(1-5 ng/ml) and a detection limit of 11.56 pM. The ability to rapidly sense IFN-γ within 
this sensing range makes the developed electrochemical platform conducive towards in-
field disease detection of a variety of diseases including paratuberculosis (i.e., Johne’s 
Disease).  Furthermore, experimental results were numerically validated with an analytical 
model that elucidated the effects of the sensing process and the influence of the 
immobilized ternary monolayer on signal output.  
Carbon allotropes have revolutionized electrical, optical, thermal, mechanical., 
chemical and sensing phenomena., and the application of which into electrochemical-based 
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biosensing demonstrates significantly increased sensitivity. Here, the first use of vertically 
aligned carbon nanotube array (VANTA) grown via chemical vapor deposition in a 2D 
IDE footprint with a high height-to-width aspect ratio (3:1 or 75:25 µm) is presented.  They 
were utilized in two biosensing projects in this dissertation. The VANTA-IDE was first 
functionalized with an antibody (Ab) specific to the human cancerous inhibitor PP2A 
(CIP2A)—a salivary oncoprotein that is associated with a variety of malignancies such as 
oral, breast, and multiple myeloma cancers.  The resultant immunosensor is capable of 
detecting CIP2A label-free across a wide linear sensing range (1 –100 pg/mL) with a 
detection limit of 0.24 pg/mL within saliva supernatant—a range that is more sensitive than 
the corresponding CIP2A enzyme linked immunosorbent assay (ELISA).  These results 
help pave the way for rapid cancer screening tests at the point-of-care (POC) such as for 
the early-stage diagnosis of oral cancer at a dentist’s office.  
Furthermore, VANTA with increased number of fingers and surface area was also 
applied for the detection of IL-10 and IFN- that are early stage biomarkers for Johnne’s 
disease. The resulting sensing range in diluted cattle implant supernatant covered 50-1000 
pg/ml for IFN-  with a theoretical detection limit of 95.87 pg/ml; while for IL-10, the 
sensing range included  0.1 to 30 pg/ml and a detection limit of 0.077 pg/ml. In addition, 
this biosensor presented convincing stability in different biological environment, which 
demonstrates the potential in future rapid (<35 minutes) and POC application for the 
diagnosis of Johnne’s disease without the need of pre-labeling or pre-concentration. 
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CHAPTER 1.    GENERAL INTRODUCTION 
 
1.1 Introduction 
1.1.1 Electrochemical biosensing 
Devices that register a physical, chemical, or biological change and convert that into a 
measurable signal are called sensors.1 Recognition elements, that are immobilized onto the 
sensor, enables the selective response to a particular analyte or a group of analytes.2 While 
they receive minimum or negligible interferences from other sample components.2 As a 
subclass of chemical sensors, biological sensors combine the sensitivity, represented by low 
detection limits, of electrochemical transducers with the high specificity of biological 
recognition process. 2 
Electrochemical techniques offer great promise for low cost-miniaturized and point-of-
care (POC) portable devices for a wide range of applications, especially in medical diagnosis 
and environment monitoring areas.3 It operates by reacting/binding with the biological target 
of interest to produce an electric signal proportional to the target concentration. For a typical 
electrochemical biosensor, it consists of a working electrode, a reference electrode and a 
counter electrode separated by an electrolyte. The reference electrode mostly connects to a 
high input impedance potentiostat and a counter electrode is used to complete the current flow.3  
Electrochemical techniques can be further categorized into potentiometric, amperometric, and 
impedimetric sensors due to difference in sensing applications: potentiometric sensors 
measures variation in open circuit potential; amperometric sensor measures currents from the 
reduction or oxidation of electroactive species and impedimetric sensor measures the 
impedance of the system upon immobilization of biolayers at the electrode surface.3 
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1.1.1.1 Amperometric biosensors 
Amperometric biosensors are the most omnipresent and successfully commercialized 
devices of bioelectronics.4 Its core sensing technique is based on measuring either value or 
density of current in an electrochemical cell at a constant applied potential value. Current 
density is a function of the presence in the solution of electrochemically active particles, and 
their oxidation/reduction takes place on the surface of the working electrode.  
Carbon allotropes have been widely applied into amperometric biosensing. Carbon 
nanotubes present high electrical conductivity and large length to diameter ratio.5 Their 
ability to promote the electron-transfer reactions of NADH and hydrogen peroxide suggests 
great promise for dehydrogenase- and oxidase- based amperometric biosenors.6 
Graphene is 2D nanomaterial one-atom-thick that possesses spectacular physical, 
chemical, and electrical properties and was isolated in 2004.7 From over a decade years of 
study, graphene has been making great impact in amperometric sensing area and has the 
potential for cost effective, sensitive, and selective electrochemical sensors to be derived.8 
Many research groups have reported the electro-catalysis of graphene toward sensing of 
dopamine,9 glucose,10 hydrazine,11 nitric oxide,12 β-nicotinamide adenine dinucleotide 
(NADH)13 and paracetamol.8,14 The results of them showed improved sensitivity and 
selectivity, facilitating lower limits of detection and offering quick response time over other 
analytic methods.8 
 
1.1.1.2 Potentiometric biosensors 
Potentiometry is one of the oldest instrumental methods and has well-established 
position in the sensoric analysis. It allows the determination of a wide spectrum of ions and 
also as it applies portable and inexpensive equipment.15 The research group led by Crepso et 
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al. showed that singled-walled carbon nanotubes (SWCNT) can act as an efficient ion to 
electron transducers in potentiometric analysis. The notable charge transfer capability 
between heterogeneous phases of SWCNTs and their remarkable double layer capacitance 
lead to SWCNT’s excellent transducing behavior.16 Moreover, SWCNTs can be easily 
deposited on many surfaces and be fabricated into solid contact electrode easily.16 Gustavo’s 
group reported the utilization of carbon nanotube based electrodes functionalized with the 1-
pentylamine molecule (CH3(CH2)4NH2). This molecule represents the five carbon spacer 
between the carbon nanotube and the aptamer as well as carbon nanotube based electrodes 
without any other chemical modification.16 This fabricated potentiometric biosensor can 
successfully detect living microorganisms in a assay in close to real time.gus16 
An ion selective potentiometric electrode fabricated by the Claussen group using 
inkjet printed graphene presented high electron mobility, nominal surface area and tensile 
strength as well as relative ease or conduciveness to functionalize graphene with 
biorecognition agents.17 The resultant thermally annealed electrodes are converted into 
potassium ion selective sensor via functionalization with a poly(vinyl chloride) membrane 
and valinomycin ionophore. Through futher electrochemical sensing, the developed sensor 
displays a wide linear sensing range of 0.01-100 mM, a low detection limit of 7 µM, a 
minimal drift of 8.6 ×10-6 V/s and a negligible interference during electrochemical potassium 
sensing against the backdrop of interferon ions.17 
 
1.1.1.3 Impedimetric biosensors 
Impedimetric biosensing is sensitive to changes in interfacial impedance upon bio-
recognition events occurring at the surface/electrolyte interface.18 With the advance of 
nanotechnology, electrochemical impedance measurements using nanoelectrodes offer 
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enormous advantages including reduced double layer capacitance, fast convergence to 
steady-state signal, enhanced current density arising from increased mass transport at the 
working electrode interface, low detection limits and improved signal to noise ratio.19 
Graphene, as a two-dimensional sheet of sp2 conjugated atomic carbon, has stimulated 
intense research because of its unique band structure, massless fermions and ultrahigh carrier 
mobility.20 In addition to that, it has 2630 m2g-1 surface area that is high to afford an 
ultrahigh loading capacity for biomolecules and drugs.21 In 2011, it was reported that the 
integration of graphene sheets could be applied for the detection for sequence-specific DNA. 
The dynamic detection range was from 1.0 × 10−12 to 1.0 × 10−6 M with a detection limit of 5.0 × 
10−13 M, which indicated that the label-free electrochemical strategy based on functionalized 
graphene exhibited high sensitivity.21 
Carbon nanotube with anomalous electrical conductivity, biocompatibility and aspect ratio 
can be fabricated in lengths of several microns, making them capable of providing signals 
transmission over relatively larger distances between the sensing region and the reading pads.22 As 
one application, antibodies specified as cancer biomarkers can be conjugated to the carbon 
nanotube side walls and enhance cell-CNT interaction. This in turn would alter the electrical 
response of the tubes.22 Vertically aligned nitrogen-doped carbon nanotube electrodes were 
studied and tested for the detection of lysozyme detection, and the resulting sensing limit reached 
100 fM and sensing range up to 7 pM.23 They also demonstrated the feasibility and reliable use of 
the lysozyme sensing assay in clinical samples through the analysis of serum samples from 
healthy and inflammatory bowel disease infected patients.23 
1.1.2 Interdigitated electrodes 
Macro-sized metal rods or wires were primarily used as electrodes immersed in the 
medium to measure the impedance. In order to miniaturize the sensor and improve the 
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sensitivity, microelectrodes, integrated with traditional detection systems, have now been 
utilized as potential candidate. It is due to the fact that microelectrodes offer a greater rate of 
reactant supply and require lower concentrations of electro-active ions to form double layer 
as compared to macroelectrodes.24 Thus microelectrodes enables the possibility of 
impedemetric sensing in low conductivity solution, where macroelectrodes may not be 
sensitive.24  
Interdigitated electrodes (IDE), fall within the category of microelectrodes, present 
promising advantages in terms of low ohmic drop, fast establishment of steady state, rapid 
reaction kinetics and increased signal to noise ratio.24,25 They consist of a series of microband 
electrodes in which alternating microbands are connected together, forming a set of 
interiditating electrode fingers. Since anodic and cathodic electrodes are closely packed 
together, minute amounts of ionic species can be efficiently (>0.98) cycled between the 
electrodes.26 Consequently, IDE eliminates the need for a reference electrode and provides 
simple measns for obtaining a steady state current response, especially compared to three and 
four electrode set-up.27 
 
1.1.3 Biorecognition agents 
Biosensors include biological recognition agents that selectively react with the target 
analyte and produces an electrical signal that is related to the concentration of the analyte 
being studied.  Common recognition agents are enzymes, proteins, antibodies, nucleic acids, 
cells, tissues or receptors, and based on their nature and sensing process, electrochemical 
biosensors can be categorize into biocatalytic devices and affinity sensors.28  
In this dissertation, the proposed biosensors are all affinity based biosensors. They 
use the selective and strong binding of biomolecules such as antibody (Ab), membrane 
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receptors, or oligonucleotides (so called aptamers), with a target analyte to produce 
measurable electrical signals.28 Among all recognition agents, Abs have been widely utilized 
and biosensors using which are referred as immunosensors. They are large Y-shaped 
glycoprotein with MW around 150 kDa,29 and  can usually been found in blood serum, tissue 
fluids, and membrane of vertebrates.29  Abs are produced by specialized B lymphocyte cells 
of the immune system in response to the presence of a foreign molecule, so called antigen 
(Ag).29The immunoassays and affinity-based biosensors can be applied easily with full 
development and optimization. The resulting chemical consumption, waste disposal, 
expensive instruments and required maintenance also help lower the overall cost per analysis. 
Two projects from Chapter 3 and Chapter 4 applied antibodies as biorecognition agents. 
Antibodies are made by natural selection that is one of the basic mechanisms of 
evolution, while the importance of artificial, in-vitro selection was recognized much later. 
Aptamers are single strand DNAs/RNAs and are an example of functional molecules selected 
in-vitro. 30 Figure 1.1 shows the artificial process based on Systematic Evolution of Ligands 
by Exponential enrichment (SELEC).30 Compared to traditionally utilized Abs, they have 
also been studied by many researchers due to its high specificity and affinity, high 
reproducibility, and significant conformational changes upon target binding.30  
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Figure 1.1. Scheme for the Systematic Evolution of Ligands by EXponential (SELEX) 
enrichment process. A random nucleic acid library is incubated with a target molecule, and 
unbound molecules are separated from bound molecules. Bound nucleic acids are eluted, 
amplified by PCR (polymerase chain reaction) and serve as an enriched library for the next 
cycle. For every target, 6–12 consecutive cycles are performed and the final enriched library 
is cloned and sequenced. Copyright © 2007 Elsevier Ltd. 
 
1.2 Research Objectives 
The long-term goal is to identify and develop a novel biosensor system that is capable 
of simultaneous and rapid detection of biomarkers for POC application. The specific 
objectives for each project are as follows: 
1) To evaluate whether proposed material is sensitive and biofunctionalzation protocol 
can immobilize biorecognition agents onto the surface of the IDE. 
2) To test whether the fabricated biosensor can detect biological target in an ideal 
sensing environment, mostly PBS buffer solution with redox probes. Calculate the 
resulting linear sensing range and detection limit. 
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3) To evaluate the sensor in a complicated biological environment or real sensing 
environment with added interferences. The purpose is to test the feasibility and potential 
of utilizing a sensor for practical application. 
4) To further understand the electrical/biological activity of each sensor from the 
application of equivalent circuit, finite element analysis and model fitting. 
 
1.3 Dissertation Overview 
In chapter 1, a general introduction to the research is introduced, which includes some 
major concepts related to impedance based biosensor and the application of IDE. This 
dissertation contains three projects that are detailed presented in chapter 2-4. The first project 
(chapter 2) introduces a ternary monolayer that consists both of an aptamer and two short-
chain thiolated monolayers that subsequently absorb on the biosensor surface. This ternary 
monolayer was immobilized on a gold IDE to demonstrate its effectiveness in sensitively and 
selectively detecting interferon gamma (IFN-γ)—a strong proinflammatory cytokine with 
direct antiviral activity, antiproliferative effects, as well as differentiation inducing and 
immunoregulatory properties.25 This ternary monolayer was first applied on a gold surface 
first due to the wealth of information that can be found in the literature regarding gold 
surface chemistry and biosensing.  It enables the feasibility of translating this knowledge to 
other carbon nanomaterial-based biosensors that haven already been developed by the 
Claussen Lab.  
In the second and third projects (chapter 3 and 4), a 3D VANTA IDE is constructed 
for the detection of oral cancer biomarkers in human saliva.  Carbon nanotubes (CNTs) are 
known to be reliably grown with a process called chemical vapor deposition (CVD). In this 
work, a novel fabrication method that involves vertically grown CNT forests and then back 
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filling them with amorphous carbon was developed. This process produces these 
nanostructures maintaining their 3D shape during electrochemical biosensing. This CNT 
architecture has multifold advantages: it mechanically strengthens the structure/devices while 
providing support to the forest as well as it creates a high surface area environment well-
suited for electrochemical biosensing. Eventually, these vertically pointed CNT forests have 
been patterned with optimized geometry into interdigitated electrode arrays for impedance 
spectroscopy experiments—the electrochemical sensing modality used in this work.  Finally, 
antibodies that are selective to CIP2A were immobilized on to the IDE and electrochemical 
detection of CIP2A was tested. Mathematic analysis and equivalent circuit fitting were both 
applied to better study this sensing scheme. 
 For the last project (Chapter 4), VANTA IDE with increased finger number and 
contact area were further studied by integrating the detection of IL-10 and IFN-, which are 
biomarkers for cattle paratuberculosis. It has recently been shown that evaluation of multiple 
cytokines rather than a single cytokine parameter enhances accuracy of these assays, as well 
as providing important biomarkers of disease progression.31 Specifically a ratio between IFN-
γ and IL10 has been successfully used for diagnosis and prediction of disease outcomes in 
humans with tuberculosis.32Amount of antibody onto the electrode surface was studied as 
well to ensure better sensing activity.  
In the last chapter, chapter 5, a general conclusion of the research work is presented 
and recommendations for future work are suggested. 
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CHAPTER 2.    RAPID AND LABEL-FREE DETECTION OF INTERFERON 
GAMMA VIA AN ELECTROCHEMICAL APTASENSOR COMPRISING A 
TERNARY SURFACE MONOLAYER ON A GOLD INTERDIGITATED 
ELECTRODE ARRAY 
This chapter is modified from a paper published in “ACS Sensors, 2, 2, 2017” 
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2.1 Abstract 
A label-free electrochemical impedance spectroscopy (EIS) aptasensor for rapid 
detection (< 35 mins) of interferon-gamma (IFN-γ) was fabricated by immobilizing a RNA 
aptamer capture probe (ACP), selective to IFN-γ, on a gold interdigitated electrode array (Au 
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IDE). The ACP was modified with a thiol group at the 5’ terminal end and subsequently co-
immobilized with 1,6-Hexanedithiol (HDT) and 6-Mecapto-1-hexanolphosphate (MCH) to 
the gold surface through thiol-gold interactions.  This ACP/HDT-MCH ternary surface 
monolayer facilitates efficient hybridization with IFN-γ and displays high resistance to non-
specific adsorption of non-target proteins [i.e., fetal bovine serum (FBS) and bovine serum 
albumin (BSA)].  The Au IDE functionalized with ACP/HDT-MCH was able to measure 
IFN-γ in actual FBS solution with a linear sensing range from 22.22 pM to 0.11 nM (1-5 
ng/ml) and a detection limit of 11.56 pM. The ability to rapidly sense IFN-γ within this 
sensing range makes the developed electrochemical platform conducive towards in-field 
disease detection of a variety of diseases including paratuberculosis (i.e., Johne’s Disease).  
Furthermore, experimental results were numerically validated with an analytical model that 
elucidated the effects of the sensing process and the influence of the immobilized ternary 
monolayer on signal output. This is the first time that ternary surface monolayers have been 
used to selectively capture/detect IFN-γ on Au IDEs.  
 
2.2 Introduction 
Interferon gamma (IFN-γ) is a strong proinflammatory cytokine with direct antiviral 
activity, antiproliferative effects, as well as differentiation inducing and immunoregulatory 
properties.1  IFN-γ is primarily produced by activated natural killer and T helper cells of the 
Th1 subset, as well as activated CD8+ cytotoxic cells of the TC1 phenotype.2  IFN-γ is crucially 
important for generating an effective cell mediated immune response (Th1) to a pathogen,4 and 
subsequently elevated levels of IFN-γ can be an early indicator of multiple diseases including 
tuberculosis,3 HIV,4 Crohn’s disease,5 cancer,6 and paratuberculosis7 (i.e., Johne’s disease).  
The quantification of IFN-γ concentrations in serum and blood samples through various 
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analytical techniques has been explored to further understand the immunological response 
during disease progression, as well as for the development of rapid diagnostic tools.6,8–10  
Current laboratory methods for detecting IFN-γ are based on an IFN-γ release assay. 
Here, peripheral blood mononuclear cells are stimulated with appropriate antigen, and the 
resulting IFN-γ level can be evaluated by a sandwich enzyme-linked immunosorbent assay 
(ELISA), enzyme-linked immunospot assay (ELISPOT), or reverse transcriptase polymerase 
chain reaction (RT-PCR).11  Though these techniques can detect IFN-γ at biologically relevant 
concentrations (e.g., 5-10 pg/ml for tuberculosis,12 15 pg/ml for HIV10 and 7.4 pg/ml for 
Crohn’s disease13)  they are arduous, expensive, and time consuming.  Furthermore, these 
techniques, in most cases, require transportation of samples and trained technicians to conduct 
the diagnostic tests in the laboratory setting—thus ELISA, ELISPOT and PCR are generally 
not amenable to rapid, in-field biodetection.11,12 Besides these conventional laboratory 
methods, other more rapid sensing methods for IFN-γ have been developed including field 
effect transistor based biosensors (Bio-FETs) and Förster resonance energy transfer (FRET) 
aptamer beacons.4,14-15 These reported biosensing techniques display tremendous promise 
toward sensitive and rapid IFN-γ sensing with detection limits extending down into the 
nanomolar and even picomolar regimes.  However, BioFETs that are comprised of micro/nano 
components require extensive cleanroom manufacturing steps (e.g., deposition of active 
source/drain regions, nano/microwire gate development, gate oxide growth, metal contact and 
reference electrode deposition, and passivation layer formation) that substantially increase the 
cost of the biosensor and decrease its reproducibility (e.g., any crack/break in the passivation 
layer would interfere with the sensor signal during biological sensing).16 FRET-based aptamer 
beacon biosensors require labeling the target analyte with a fluorescent tag, a procedure that 
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requires laboratory processing that is not conducive towards rapid in-field sensing. Likewise, 
FRET-efficiency depends on a variety of variables (e.g., nature of dyes, spacer length or dye-
dye interactions) that are difficult to characterize with in-field sensor equipment and highly 
variable with in-field biological samples.4,17,18  Electrochemical impedance-based biosensors 
circumvent these challenges by offering relatively facile fabrication procedures, label-free 
operation, and rapid (< 35 mins) in-field sensing.8,19–21 Furthermore, the use of an aptamer 
capture probe (ACP) as the biorecognition agent has shown promise in improving both the 
specificity and sensitivity of more conventional antibody-based detection schemes.4,22,23 In 
fact, several aptasensors have been developed for the detection of IFN-γ.15,24–26 These 
biosensors show promise for rapid detection of IFN-γ, however, they require DNA hairpin 
structures and/or signaling probe labels that increase biosensor complexity and decrease the 
reliability of IFN-γ detection in actual serum samples 24,25 Some of these biosensors are also 
designed to detect IFN-γ at extremely low concentrations (down to picomolar ranges that are 
promising/necessary for tuberculosis detection/identification) while not demonstrating the 
capability to detect IFN-γ at higher concentration ranges that are necessary for potential 
Johne’s disease detection (considered positive when IFN-γ concentration is > 1ng/ml)26–29.   
    Herein we report the first interdigitated electrode (IDE) for IFN-γ detection with the 
use of immbolized RNA apatmers without the need for target analyte labeling.  An Au IDE 
with 500 microbands (individual microband width = 5 μm) is used to detect IFN-γ via 
electrochemical impedance spectroscopy (EIS). It should be noted that such IDE-based 
biosensors experience advantageous mass transport and reaction kinetics effects (nonplanar or 
radial diffusion to each individual microband or IDE finger), higher current densities (electrical 
field lines are concentrated around tightly packed microbands), and favorable Faradic-to-
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capacitive current ratios that lead to improved biosensor signal-to-noise ratios and hence higher 
sensitivity and lower detection limits for enhanced detection of  antibody-antigen or aptamer-
target binding events.30–34   A surface ternary monolayer consisting of 6-Mecapto-1-
hexanolphosphate (MCH) /1,6-Hexanedithiol (HDT) is also immobilized onto the Au IDE to 
impede non-specific adsorption of non-target, endogenous species and subsequently improve 
the biosensor selectivity.  The immobilization of both the ACP and surface ternary monolayers 
onto the Au IDE is characterized by EIS in the presence of the redox couple [Fe(CN)6]3-/4- and 
the density of immobilized ACP is tuned with the aid of atomic force spectroscopy (AFM) and 
EIS analysis.  To better interpret the immobilization and sensing process, an equivalent circuit 
model is developed to explain in part the interfacial change between the electrolyte-electrode 
interface. This theoretical model validates the experimental data by elucidating the relationship 
between the biosensor signal output, viz., electrochemical impedance, and the double 
capacitance of both a bare (unfunctionalized) Au IDE and an Au IDE functionalized with the 
ACP/HDT-MCH surface ternary monolayer.   
 
2.3 Methods Section 
2.3.1 Chemicals  
Bovine serum albumin (BSA), potassium chloride, Tris-EDTA buffer solution, 1,6-
Hexanedithiol (HDT), 6-Mecapto-1-hexanolphosphate (MCH), buffered saline and 
potassium, Tris(2-carboxyethyl(phosphine hydrochloride (TCEP), hydrogen peroxide 
solution (30% wt. % in H2O), sulfuric acid (95%-98%), and hexacyanoferrate trihydrate 
were purchased from Sigma-Aldrich (USA). Fetal bovine serum (FBS) was obtained from 
GIBCO ThermoFisher Scientfic while nuclease free water, potassium ferricyanide, and 
bovine IFN-γ recombinant protein (45 kDa) from ThermoFisher Scientfic. 
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2.3.2 Au IDE preparation 
Au IDEs (Dropsens:  G-IDEAU5) consisting of 500 fingers with both thickness and 
spacing of 5 µm and a finger length of 6760 µm were used as the biosensor electrode.  The 
Au IDEs were cleaned with both Piranha solution (3:1 ratio of concentrated sulfuric acid vs. 
hydrogen peroxide) and bath sonication (ethanol and then water for 30 min each 
respectively) and subsequently dried under an argon gas stream before ACP 
biofunctionalization.   
 
2.3.3 Au IDE biofunctionalization 
The Au IDEs were functionalized with both an ACP probe and ternary monolayer 
(ACP/HDT-MCH) before electrochemical IFN-γ biosensing.  First, an RNA ACP was 
purchased from Gene Link  with a sequence of 5’ -GGG AGG ACG AUG CGG ACA CCG 
UUA AUC UGA GGC CCU GUC CUA UUC CUU CAC GCC UCA GA-3’.35  This ACP 
was selected for its high binding affinity (Kd= 18.7 ± 1.2 nM) to IFN-γ.36 The truncated 
sequence of the ACP eliminates nucleotide stretches that are not critical for direct interaction 
with the target, but can fold into the necessary structures to facilitate target binding.22  The 
5’ terminal end was modified with a thiol SS-C6 group to enable thiol-gold binding to the Au 
IDE surface.  The ACP probe was received in the lyophilized form and decapped with Tris(2-
carboxyethyl) phosphine hydrochloride (TCEP) by performing the following steps: 400 µl of 
0.1 M TCEP was directly added into the lyophilized thiolated ACP and left at room 
temperature for 1 hr with intermittent vortexing; next 50 µl of 3 M sodium acetate at pH 5.2 
and 1.5 ml of  ethanol were added to the solution; next the resulting mixture was kept at -
20°C for 20 min to separate ACP from the solution; finally the solution was removed from 
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the freezer and centrifuged at 12k rpm for 10 min to decant ethanol and dry pellets in air.  
The decapped ACP was subsequently dissolved in 1 µM tris-HCl (TE) buffer. Au IDEs 
functionalized with ACP only were functionalized via drop coating with 20 μl of 500 nM 
ACP solution. Au IDEs functionalized with both ACP and HDT-MCH were created by first 
drop coating 20 μl of a solution containing 500 nM of ACP probe and 3 mM of HDT onto 
the Au IDE followed by dropcoating 20 uL of 1 mM MCH. Both distinctly functionalized Au 
IDEs were permitted to incubate for 30 min before rinsing thrice with nuclease free water 
and drying under a stream of inert argon gas to remove unbound/non-specifically adsorbed 
IFN-γ.37. Finally, the functionalized Au IDEs were placed in a humidity chamber and stored 
at 4°C in the dark overnight before electrochemical biosensing. 
 
2.3.4 Electrochemical detection of IFN-γ 
.  Electrochemical impedance measurements were obtained from a CHI 6273E 
potentiostat (CHI instrument, USA), and a two-electrode setup was utilized (one side or one 
finger comb of the IDE as the working electrode and the other side as the reference 
electrode).  Functionalized Au IDEs were tested in a vial containing a 5mM [Fe(CN)6]3-/4- 
redox probe and 0.1 M KCl salt within a 1 X PBS (0.01M) (pH 7.0) solution.  Varying 
concentrations of IFN-γ (1 ng/ml, 2 ng/ml, 3 ng/ml, 4 ng/ml, 5 ng/ml, 10 ng/ml, 60 ng/ml, 
100 ng/ml and 200 ng/ml) were electrochemically detected by monitoring the impedance 
spectra/Nyquist plots using impedance spectroscopy ranging from 0.1 Hz to 100 KHz with an 
applied sine potential of 40 mV. Bovine IFN-γ recombinant protein diluted in 1 X PBS with 
1% BSA was used to perform the IFN-γ characterization tests. Before EIS measurements 
were obtained, the aptamer functionalized Au IDEs were incubated with the target antigen 
for 30 mins before EIS sensing, which requires approximately 2 mins.  Therefore, the total 
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aptasensor test time, including both incubation and electrochemical sensing time, requires 
less than 35 mins. 
 
2.3.5 Electrochemical interference testing 
The Au IDEs biofunctionalized with ACP only and ACP/HDT-MCH were tested for 
sensitivity towards FBS and BSA. These interference tests were conducted by utilizing one 
of the following protocols: increasing the concentration of BSA (1 ng/ml, 100 ng/ml and 
1000 ng/ml) or increasing incubation times with pure FBS (5 min, 15 min, 30 min and 60 
min). EIS was subsequently utilized to evaluate the change of charge transfer resistance after 
said incubations. 
2.4 Results and Discussion 
 
2.4.1 Au IDE biofunctionalization strategy 
The use of mixed self-assembled monolayers (SAMs) in conjunction with a thiol-
derivatized DNA or aptamer capture probe and spacer thiols (e.g., MCH) functionalized on 
gold surfaces has been used to improve both the hybridization efficiency and reproducibility 
of the biosensors35–38. These preliminary reports of mixed SAMs were comprised of binary 
monolayers that suffered from surface defects (i.e., incomplete backfilling) that created issues 
with biosensor reproducibility.  To circumvent these challenges research groups have added a 
third thiol component to help improve the filling density of the SAM and hence improve 
nonspecific adsorption of non-target analyte to the Au surface.39–41 In this work, we utilize the 
HDT and MCH in conjunction with a RNA ACP to create a ternary surface monolayer that can 
be immobilized on the surface of the Au IDE to selectively detect IFN-γ in biological solutions 
(Figure 2.1).  The Au IDEs were biofunctionalized with the ACP/HDT-MCH ternary surface 
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monolayer via thiol-Au chemisorption following similarly published protocols and as 
explained in detail in the Experimental Section.41–44  Briefly, the ACP was subsequently co-
immobilized with 1,6-Hexanedithiol (HDT) to 
the Au IDE through thiol-Au interactions along 
with 6-Mecapto-1-hexanolphosphate (MCH) 
acting as a diluent.  The dithiol HDT aligns 
horizontally with the Au surface instead of 
orthogonally, and subsequently more 
effectively backfills SAMs on Au surfaces 
compared to vertically aligned thiol groups, 
which cannot bridge over irregular/rough 
surfaces.41 Thus, this ternary surface 
monolayer has less non-specificity from non-
target proteins than ternary monolayers 
produced with vertical thiol monolayers [e.g., 
cyclic dithiol dithiothreitol (DTT)] or binary thiol monolayers.35–38 In order to assess the effects 
of the ternary surface monolayer on biosensor selectivity, Au IDEs were functionalized with 
the ACP only (Figure 2.1a) as well as with the ternary monolayer, ACP/HDT- 
MCH (Figure 2.1b).  The height and concentration of ACP immobilized on a both a mica 
surface and AuNPs were characterized via atomic force microscopy.  The average height of the 
immobilized ACPs was measured to be 4.8 nm which correlates well with the height of the 
approximate 15 free base pairs (Bps) of the 3-loop RNA-based ACP, and note that the height 
of 15 RNA Bps is ~5.1 nm as each RNA Bp is ~0.34 nm).  
Figure 2.1.  Biofunctionalization scheme 
of the gold interdigitated electrodes (Au 
IDEs). Magnified view showing 
biofunctionalization with (a) the aptamer 
capture probe (ACP) and (b) ACP with 
1,6-Hexanedithiol (HDT) and 6-
Mecapto-1-hexanolphosphate (MCH) 
which forms the ternary monolayer 
structure.   
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IFN-𝜸 Detection Using Electrochemical Impedance Spectroscopy. The developed 
aptasensors functionalized with and without HDT/MCH thiol backfillers were 
electrochemically characterized before IFN-γ sensing (see Figure 2.2). Nyquists plots 
(imaginary impedance Z’’ versus real impedance Z’), displayed a semicircular pattern that 
increases in magnitude with the complexity of bioconjugation (ACP/HDT-MCH on AuIDE > 
ACP/HDT on AuIDE  > bare AuIDE) (Figure 2.2).  At higher frequency, the semicircle 
portion corresponds to a direct electron transfer limited process, while the decrease of 
frequency yielded a straight line portion (AuIDE only, see Figure 2.2), which represents a 
diffusion controlled electron transfer process.19 Hence, modification of the working electrode 
surface with an organic layer tended to decrease the double layer capacitance and delayed the 
interfacial electron transfer rate as compared to a bare working electrode,31-33 which is also 
illustrated in Table 2.1.  Furthermore, both the AuIDE biofunctionalized with ACP/HDT-
MCH and ACP only were tested with 10 ng/ml and 100 ng/ml of IFN-γ to demonstrate that 
the binding of IFN-γ to the aptasensor further decreased the double layer capacitance and 
delayed the interfacial electron transfer rate.  In other words, the ACP immobilized on the 
AuIDE was able to successfully bind to the target analyte (i.e., IFN-γ) and change the charge 
transfer resistance of the AuIDE in a measurable way with and without the presence of the 
thiolated backfillers (i.e., HDT and MCH).  Therefore, IFN-γ could still be measurably 
detected by the ACP functionalized electrode with the presence of HDT/MCH backfillers that 
tend to reduce noise from non-specific adsorption and hence improves the signal-to-noise 
ratio of the sensor.  
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Figure 2.2. (a highlighted in red) Nyquist plots obtained via EIS with the following 
electrodes: AuIDE electrode without surface functionalization in ferricyanide solution (Bare 
electrode), Au IDE that is functionalized only with the thiolated backfillers (i.e., HDT and 
MCH) in ferricyanide solution, Au IDE that is functionalized with both the capture probe 
(ACP) and the thiolated backfillers, viz., HDT and MCH in ferricyanide solution, and AuIDE 
functionalized with ACP/HDT-MCH in ferricyanide solution with 10 and 100 ng/ml of IFN-γ 
respectively.  (b highlighted in blue) Nyquist plots obtained via EIS with the following 
electrodes:  AuIDE electrode without surface functionalization in ferricyanide solution (Bare 
electrode), AuIDE electrode that is functionalized only with the ACP in ferricyanide solution, 
and AuIDE functionalized with ACP only in ferricyanide solution with 10 and 100 ng/ml of 
IFN-γ respectively.  
23 
 
 
 
Next, the ACP (Figure 2.3 a, c, & e) and ACP/HDT-MCH (Figure 2.3 b, d, & f) 
functionalized AuIDEs were electrochemically characterized for IFN-γ sensing via EIS. Note 
that Figure 2.3b also shows the EIS response (albeit nearly negligible) for an un-
functionalized or bare electrode.  The change of magnitude of the charge transfer resistance 
from the aptasensor without the thiol backfiller is much higher than with the backfiller, since 
there was nonspecific binding that occurred, which means the free-floating carrier protein 
from IFN- γ was adhered to the exposed gold area.  The collected data was then analyzed by 
plotting the percentage of change of charge resistance (∆R) versus increased concentration of 
IFN- γ where ∆R =Rct -Ro with Rct referring to the measured charge transfer resistance and Ro 
the charge transfer resistance of the electrode functionalized with ACP (Figure 2.3 c-f). 
Linear regression analysis from three distinct experiments showed that both the ACP and 
ACP/HDT-MCH modified Au IDE electrodes displayed a linear sensing range across an 
IFN- γ concentration range of 22.22 pM to 0.22 nM (1-10 ng/ml) with a coefficient of 
determination (R2) of 0.90 and 0.99 respectively. The detection limit of the ACP only and 
ACP/HDT-MCH modified Au IDE electrodes was calculated to be 0.73 ng/ml and 0.91 
ng/ml, respectively, via the method detection limit (MDL)45 with data acquired from three 
standard deviations of 7 distinct test trails. It should be noted that the MDL method is more 
accurate compared to the conventionally utilized instrument detection limit method that is 
commonly reported.45,46  
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Figure 2.3.  Electrochemical detection of IFN-γ for the Au IDE functionalized with 
ACP/HDT-MCH and ACP only (a, c, & e highlighted in red) and (b, d, & f highlighted in 
blue) respectively.  Nyquist plots showing impedance changes with incremental IFN-γ 
concentration increases of 1 ng/ml, 2 ng/ml, 3 ng/ml, 4 ng/ml, 5 ng/ml, and 10 ng/ml for the 
(a) ACP/HDT-MCH-Au IDE (b) ACP-Au IDE respectively.  The resultant percentage of 
change of charge resistance versus concentration of IFN- γ across a broader range of 
concentration increases (1 ng/ml, 2 ng/ml, 3 ng/ml, 4 ng/ml, 5 ng/ml, 10 ng/ml, 60 ng/ml, 
100 ng/ml and 200 ng/ml) for the (c) ACP/HDT-MCH-Au IDE and (d) ACP-Au IDE 
respectively.  IFN-γ linear sensing range of the (e) ACP/HDT-MCH-Au IDE (f) ACP-Au 
IDE respectively.  Note Log(C) refers to the log concentration of IFN-γ measured in g/ml. 
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2.4.2 Aptasensor selectivity experiments 
The ACP only and ACP/HDT-MCH functionalized Au IDEs were characterized for 
sensitivity to background interfering proteins including FBS and BSA (Figure 2.4).  Figure 
2.4a shows the electrochemical response of the aptasensors with increasing incubation times 
(5 min, 15 min, 30 min and 60 min) of pure FBS (see Experimental Section).  These selectivity 
experiments show that Rct does not change for the Au IDEs modified with the ternary 
monolayer ACP/HDT-MCH, while the Au IDE modified with ACP only exhibited increasing 
Rct in the presence of the target. Next, both the ACP and ACP/HDT-MCH functionalized Au 
IDEs were tested for their sensitivity towards solutions containing various concentrations of 
BSA (e.g., 1 ng/ml, 100 ng/ml and 1000 ng/ml) (Figure 2.4b).  Results of the BSA interference 
tests displayed similar results to those conducted with FBS in that the resulting Rct remained 
relatively constant (unchanged) with Au IDEs modified with ACP/HDT-MCH while those 
modified with ACP only did not. This higher specificity of the ACP/HDT-MCH functionalized 
Au IDE corroborates previous reports where DNA-based ternary monolayers showed similar 
higher specificity than electrodes without.41  
In order to further test the selectivity of the developed aptasensor, the ACP/HDT-
MCH functionalized Au IDE was used to detect IFN- γ in actual FBS solutions (Figure 2.4c 
& 4d).  Figure 2.4c shows the change of impedance with increasing concentrations of IFN- γ 
(1ng/ml to 10 ng/ml) in FBS solution, the change of impedance saturates when the 
concentration reaches 6 ng/ml while Figure 2.4d shows the linear sensing range is between 
1-5 ng/ml [fitted line equation y = 49.0 x + 28.8 (R² = 0.95)] with a theoretical detection limit 
of 0.52 ng/ml. Based on these results, this electrochemical platform could be used for 
detection of influenza induced respiratory infections (0.83 ng/ml),47 paratuberculosis (i.e., 
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Johne’s Disease in cattle, > 1 ng/ml),27 tuberculosis pleural effusions (1.493 ng/ml),48 and 
multiple myeloma (1-10.7 ng/ml).49 
 
Figure 2.4. (a & b) Selectivity experiments were AuIDEs functionalized with ACP and 
ACP/HDT-MCH were tested for sensitivity to FBS or BSA. (a) Interference test performed 
in pure FBS were each electrode was exposed to FBS at various incubation times (5 min, 15 
min, 30 min and 60 min) before testing. (b) Interference test in solutions containing varying 
concentrations of BSA (1 ng/ml, 100 ng/ml and 1000 ng/ml) were each electrode was 
incubated for 30 min before testing.  (c) ACP/HDT-MCH functionalized Au IDE sensing 
IFN-γ within pure FBS over a concentration range of 1-10 ng/ml and over a linear sensing 
range of (d) 1-5 ng/ml. 
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2.4.3 Equivalent circuit model 
.  An equivalent circuit model was also created to help elucidate the physiochemical 
underpinnings of the obtained EIS experimental data (Figure 2.4).  Such an equivalent circuit 
has been used in various forms to model the electrical/electrochemical behavior of 
interdigitated electrodes.50–52 Details regarding the set-up of this model including key 
parameter definitions can be found in the 
Supporting Information, however, Rwire and 
Rsol, parameters commonly found in such 
equivalent circuit models, were omitted 
because their values were negligible—the 
IDE-to-potentiostat connecting wire (Rwire) 
exhibited a negligible resistance (< 1 ) and 
the added solution electrolytes (i.e., KCl and 
PBS) lowered the Rsol to a negligible level (~ 
0 ;  note Nyquist plot starts at the origin 
(0,0) in Figure 2.2, 2. 3, & 2.5).  Also, the 
proposed equivalent circuit model portrays 
only one of the IDE finger comb electrodes 
(Figure 2.5a & 2.5b) as each of the IDE 
electrode finger combs are symmetrical and 
therefore modeling them both would be 
redundant.  Furthermore, in this model, the 
Figure 2.5. Computational model and 
comparison of model results with 
experimental data. (a) Theoretical 
equivalent circuit model of the aptasensor 
and (b) actual circuit model used in this 
work.  Note that Rs and Rwire are 
negligible and therefore excluded from 
the circuit model. (c) Experimental and 
model simulation Nyquist plots of the 
ACP/HDT-MCH-AuIDE. 
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Cdl, was treated as a constant phase element (CPE) in lieu of an ideal capacitor.53  A CPE is a 
frequency dependent element that reciprocates between a resistor and a capacitor depending 
on the applied frequency and thus is a more accurate depiction of the behavior associated 
with an IDE.  
The simulation output values (Rct, Ko, n, Y, I, Cdl) are presented in Table 2.1 and the 
resultant model simulation Nyquist plot was fitted to experimental data (Figure 2.5c). Table 1 
lists the simulated values of Rct based on the amount of biological targets attached to the 
electrode surface. The variables Y and n represent the coefficient of the CPE and the exponent 
factor of the CPE respectively, where n is equal to one when the CPE is acting as an ideal 
capacitor and n is equals to zero when the CPE behaves like an ideal resistor (see Eq. 1).53 
Also note that j is the imaginary number, ω is frequency, and Q has the numerical value of the 
admittance (1 / |Z|) at 𝜔 = -1/rad/s in Equation 1.54  The current exchange density (io) needed 
to calculate the charge transfer rate constant Ko was evaluated from Eq.2 [where R is the gas 
constant (8.3145 J/molK), T (K) is the temperature, and n is the number of electrons].  
Subsequently, Ko was determined from Eq.3 where A is the area of the electrode and C is the 
concentration of the electrolyte. Finally, Cdl is estimated from Eq.4. 
             𝑌 =
1
𝑄(𝑗𝜔)𝑛
                                                                    (1)   
 𝑅𝑐𝑡 =
𝑅𝑇
𝑛𝐹𝑖0
                                                                    (2) 
       𝑖0 = 𝑛𝐹𝐴𝐾𝑜𝐶                                                            (3) 
𝜔 = 2𝜋𝑓 =
1
𝑅𝑐𝑡𝐶𝑑𝑙
                                                                 (4) 
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Table 2.1. Generated parameters from the equivalent circuit model. 
Electrode Functionalization 
Rct 
(KΩ) 
n K0  
(µm/s) 
Y 
(1×10-7) 
I 
(nA) 
Cdl 
(µF) 
Bare 34.6 0.881 91.1 28.60 742.00 2.587 
HDT +ACP 287 0.81 11 4.31 89.50 0.554 
HDT + MCH + ACP 2030 0.865 1.55 0.86 12.70 0.300 
10 ng/ml of IFN- 2690 0.972 1.17 2.82 9.53 
0.274 
0.102 
20 ng/ml of IFN- 3380 0.787 0.932 0.99 7.60 0.032 
30 ng/ml of IFN- 3560 0.974 0.884 2.73 7.20 0.031 
40 ng/ml of IFN- 3930 0.83 0.801 0.83 6.53 0.028 
50 ng/ml of IFN- 4120 0.976 0.765 2.63 6.24 0.026 
100 ng/ml of IFN- 3410 0.977 0.924 2.40 7.53 0.026 
150 ng/ml of IFN- 3560 0.974 0.884 2.73 7.20 0.031 
HDT: 1,6-Hexanedithiol  
MCH:  6-Mecapto-1-hexanolphosphate 
ACP:  Aptamer capture probe 
IFN-:  interferon-gamma 
 
  
In summary, the proposed equivalent circuit model reveals the binding activity within 
the interface between the electrolyte and electrode surface. For example,  a bare or 
unfunctionalized Au IDE exhibits a Rct value of  34.6 KΩ, while Au IDEs functionalized with 
HDT/ACP or the ternary monlayer HDT/MCH/ACP exhibit much higher Rct values (287 KΩ 
and 2030 KΩ, respectively), which is in agreement with fact that the rapid electron transfer 
rate on the bare electrode decreased due to the immobilization of blocking agents (e.g., 
thiolated monolayers such as MCH and HDT or non-specific absorption of non-target 
proteins) on the simulated IDE surface. The addition of IFN-γ also caused an increase of Rct.  
For example, as the concentration of IFN-γ increased from 10 ng/ml to 50 ng/ml, the value of 
Rct increased from 2690 KΩ to 4120 KΩ.  Since the io (measured in units of nA) and K0 
(measured in units of µm/s) is inversely proportional to the Rct, the values of io and K0 
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decrease when monolayers are added to the IFN-γ. Such chemical functionalization of the Au 
IDEs also leads to the decrease of double layer capacitance (Cdl) (Table 1). This decrease in 
double layer capacitance is most likely caused by the displacement of polar water molecules 
by less polar molecules near the electrode-electrolyte interface.55 It is also worth noting that 
the values of n, the coefficient of CPE, are all very close to one as reported in Table 1.  
Values of near unity for n highlights the fact that the double layer capacitance is acting more 
like an imperfect capacitor than a resistor during Au IDE electrochemical sensing—
confirming that the model is depicting an electrical environment associated with actual 
conductive electrode/liquid electrolyte interfaces.53 Since the simulated results correlate well 
with the experimental results (Figure 2.5c), it is conceivable that such a model could be used 
to help facilitate the optimization of both the geometrical and biofunctionalization design of 
electrochemical IDE biosensors. 
 
2.5 Conclusion 
The developed ACP/HDT-MCH ternary surface monolayer on an Au IDE facilitates 
efficient hybridization with IFN-γ to reduce non-specific adsorption of proteins found 
endogenously within FBS and BSA. This is the first report of developing an electrochemical 
IFN-γ biosensor with a ternary surface monolayer and the first electrochemical IFN-γ 
biosensor developed on an IDE array. This aptasensor is able to detect IFN-γ with a linear 
sensing region of 22.22 pM to 0.22 nM and lower detection limit of 20.22 pM (method 
detection limit technique) in buffer solution. In actual FBS solution, it detected IFN-γ with a 
linear sensing range from 22.22 pM to 0.11 nM with a detection limit of 11.56 pM. The 
ability of the biosensor to accurately detect IFN-γ in protein matrices without sample pre-
treatment or pre-detection labeling is well-suited for rapid in-field or penside biosensor 
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detection strategies. The distinct ternary surface monolayer immobilized on multiple IDEs 
fabricated on a single silicon chip can be used for multiplexed biosensing for rapid on site 
detection of diseases such as influenza induced respiratory infections, paratuberculosis (i.e., 
Johne’s Disease), tuberculosis pleural effusion, and multiple myeloma.  
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CHAPTER 3.    CIP2A IMMUNOSENSOR COMPRISED OF VERTICALLY-
ALIGNED CARBON NANOTUBE INTERDIGITATED ELECTRODES TOWARD 
POINT-OF-CARE CANCER SCREENING 
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Highlights 
 
 The first electrochemical immunosensor for the detection of CIP2A was proposed. 
 Vertically aligned carbon nanotube was first fabricated into a 3D structured interdigitated 
electrode array with increased surface area. 
 The sensor was evaluated in both PBS buffer and human saliva, indicating great stability and 
high sensitivities of 4.69 pg/ml and 0.24 pg/ml, respectively.  
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3.1 Abstract 
Vertically aligned carbon nanotube array (VANTA) coatings have recently garnered much 
attention due in part to their light absorption, chemical inertness, and electrical conductivity 
properties.  Herein we report the first VANTA interdigitated electrode (IDE) array for 
electrochemical biosensing.  The VANTA-IDE is functionalized with an antibody (Ab) 
specific to the human cancerous inhibitor PP2A (CIP2A)—a salivary oncoprotein that is 
associated with a variety of malignancies such as oral cancer, breast cancer and multiple 
myeloma.  The resultant immunosensor is capable of detecting CIP2A label-free across a wide 
linear sensing range (5 pg/mL to 400 pg/mL) and a low detection limit (4.69 pg/ml) in buffer.  
Moreover, the VANTA-IDE shows great promise in sensing in actual biological fluid as the 
biosensor was able to sense CIP2A within saliva supernatant over a concentration range of 1 –
100 pg/mL with a detection limit of 0.24 pg/mL—a range that is more sensitive than the 
corresponding CIP2A enzyme linked immunosorbent assay (ELISA).  These results help pave 
the way for rapid cancer screening tests at the point-of-care (POC) such as for the early-stage 
diagnosis of oral cancer at a dentist’s office.      
 
Keywords:  Carbon Nanotubes, Interdigitated Electrode, CIP2A, Immunosensor, Oral Cancer, 
Electrochemical Biosensor 
3.2 Introduction 
Oral cancers (OCs) are the thirteenth most common cancers in the world with 
approximately 300,000 new cases and 145,000 deaths annually.1 Despite occurring in one of 
the most accessible anatomical sites of the human body, early diagnosis of OC is challenging 
as 70% of oral malignancies are diagnosed in advanced stages.2 Hence, the prognosis of OC 
patients is generally poor as the overall 5-year survival rate for OCs is less than 40%.3  In an 
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effort to improve prognosis, a wide variety of OC screening techniques have been developed 
including visual screening,3 toluidine blue (TB) staining,4 auto-fluorescence spectroscopy,5 
exfoliative cytology,3 and biopsy/histopathology.1 However, these techniques suffer from 
issues such as low sensitivity, lack of specificity for malignant tissue, and are also time-
consuming, expensive, and labor intensive.1   
Electrochemical-based biosensors comprised of interdigitated electrodes (IDEs) and 
monitored with electrochemical impedance spectroscopy (EIS) may hold the key to point-of-
care cancer diagnostics.6–8  IDEs consist of alternating ‘finger-like’ electrodes that are 
electrically connected with a width and pitch typically in the range of 5 – 25 m.9,10  IDEs 
inherently operate well as electrochemical transducers as they exhibit low ohmic drops, large 
collection efficiencies, high signal-to-noise ratios, and fast response times.7,11–13 EIS is often 
employed as the sensing modality for IDE-based immunosensors due to its ability to detect 
small variations in resistance/capacitance which offers the potential for label-free, real-time, 
and in situ detection of various analytes.13  Moreover, electrochemical IDEs have recently 
shown tremendous promise in detecting cancer linked proteins with low detection limits and 
wide sensing ranges [e.g., 0.1 ng/mL to 1000 ng/mL for carcinoembryonic antigen (CEA),14  
0.01–100 ng/mL for human immunoglobulin A (IgA),15 and 1.0 pg/L to 1.0 μg/L for prostate 
specific antigen 16].  Although these reported IDE-based immunosensors circumvent much of 
the laboratory expertise and time associated with conventional immunoassay-based tests,17 
they typically require the use of a secondary Ab label conjugated with either a conductive 
nanoparticle or enzyme-nanoparticle bioconjugate. Such labeling techniques are utilized to 
amplify the heterogeneous charge transport at the sensor-liquid interface, because of the 
relatively insulating qualities of the biorecognition agents themselves and/or the surface 
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functionalization motifs.18–20 Consequently, such labeling requirements increase the 
complexity of the biosensing protocol and diminish the likelihood of point-of-care (POC) 
testing.  
Herein we report, the first EIS IDE immunosensor for a biomarker related to oral 
cancer, viz., CIP2A, as well as to malignancies such as breast cancer and multiple myeloma.21,22  
CIP2A is abundantly expressed in oral squamous cell carcinoma cell lines as well as dysplastic 
and malignant human oral epithelial tissues.23–25  Hence, CIP2A is a crucial biomarker that 
differentiates between someone who potentially has oral cancer and a healthy individual. 
Researchers have also found that CIP2A is induced in the premalignant stages of the carcinoma 
tissue, demonstrating that it is an indicator of an early-stage of oral cancer.26   Detection of 
CIP2A, therefore, is a critical step towards determining and predicting onset of oral cancer.  
The immunosensor developed in this work is the first to use 3D high-aspect-ratio vertically 
aligned carbon nanotube arrays (VANTAs) arranged in a 2D IDE footprint to enable rapid, 
label-free CIP2A monitoring. The high surface area of the VANTA IDEs and favorable 
materials properties of carbon nanotubes (CNTs) (e.g., high electrical conductivity, 
electrochemical reactivity, and biocompatibility)27–29 leads to a higher biosensor sensitivity 
than a comparable ELISA test kit.  Moreover, the IDE designs requires facile lithographic 
patterning to create the CNT seed catalyst metal within a micro IDE pattern. Such patterning 
requires significantly reduced cleanroom processing than other immunosensors such as field 
effect transistors (FET) with nano/microwire gate development, gate oxide growth, deposition 
of active source/drain regions, reference electrode deposition, and passivation layer 
formation.30,31  Furthermore, cracks in the passivation layer of FETs can significantly alter 
biosensor outputs leading to false positive/negative signals. The use of IDEs in conjunction 
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with an electrochemical sensing modality also eliminates the need for target analyte labeling 
with fluorophores or Förster resonance energy transfer (FRET) dye pairs that are that are 
difficult to characterize and highly variable with in-field biological and/or turbid samples32–34 
as well as the need for pre-enrichment steps that require upwards of 24–48 hours before 
biosensor signal acquisition as is the case with many lateral flow assayed 
immunosensors.32,35,36  Moreover, electrochemical sensing yields a qualitative signal that can 
report a specific target analyte concentration as opposed to many colorimetric biosensors that 
report only qualitative results.37,38   Hence, the developed CIP2A biosensors are highly 
conducive to in-field POC diagnostics. 
 
3.3 Material and Methods 
3.3.1 Design and fabrication of VANTA IDE devices 
The high-aspect-ratio VANTA IDE devices (typically consisting of multi-walled CNTs grown 
with average diameter of 20-30 nm and height of 50-80 µm) are fabricated to start with the 
growth of the nanotubes using a chemical vapor deposition (CVD) process. A silicon wafer 
with a 300 nm thick, thermally grown oxide was used as a base substrate for the device 
fabrication. An e-beam deposited Al2O3 film of 50 nm thickness is deposited onto the wafer 
using a Denton e-beam evaporator (Figure 3.1a). With an AZ3330 resist coating, the IDE 
pattern was defined by photolithography, and resist development (Figure 3.1b). A 7 nm iron 
layer is thermally evaporated onto the wafer, followed by photoresist lift off using N-Methyl-
2-pyrrolidone for 10 min, leaving the IDE-patterned iron catalyst ready for CNT growth 
(Figure 3.1c). A Lindberg/Blue M tube furnace was used for CNT growth using controlled 
flow of hydrogen (311 sccm) and ethylene (338 sccm) at 750 °C for 30 seconds (Figure 3.1d). 
To ensure a mechanically robust yet porous arrays of IDE fingers, in-situ amorphous carbon 
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infiltration into the CNT forest was made for 3 min by flowing hydrogen and ethylene (311 
sccm and 193 sccm, respectively) at 900°C (Figure 3.1d).39  In order to remove the carbon 
floor between the electrodes of the IDE, which is deposited everywhere during deposition of 
the amorphous carbon, an oxygen plasma etch was performed using a Technics Planar Etch II 
for 45 s at 250 W and 300 mTorr. 
 
3.3.2 Functionalization chemistry 
The activity of the Ag and Ab pair, were tested prior to functionalizing electrodes, 
using immunoblotting. VANTA IDEs were cleaned in 0.1 M MES buffer for 10 mins, 
followed by incubation in a solution of 0.4 M EDC and 0.1 M NHS prepared in 0.1 M MES 
buffer for 1 hr. Devices were then washed in PBS, dried with nitrogen gas to remove excess 
amount of liquid, and incubated overnight with a 1:100 (5 µg/mL) dilution of CIP2A Ab. The 
reaction was quenched with 1.0 M ethanolamine to block unbound carboxyl groups. Finally, 
the IDEs were blocked in 2% BSA for 1 hour to reduce non-specific binding of the Ag to 
bare areas of the electrode or substrate during electrochemical sensing. The functionalized 
electrodes were washed in PBS and blown with nitrogen gas. For sensing CIP2A, 20 µL of 
Ag (at indicated concentrations) was placed on the IDE and incubated for 30 min. EIS 
measurements were performed in 5 mM ferro/ferricyanide solution (Figure 4). 
3.3.3 Fluorescence spectroscopy 
Three VANTA IDEs were prepared for fluorescence spectroscopy measurements as 
follows: the first positive control electrode was biofunctionalized using the protocol written in 
the Functionalization Chemistry section; the second negative control electrode was prepared 
in a similar fashion but without the use of primary Ab; while the third electrode was a non-
functionalized bare IDE (control). Next, 10 µL of 1:200 dilution of anti-mouse IgG-FITC Ab 
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produced in goat were placed on positive and negative controlled IDEs respectively and 
incubated for 1 hr. The negative control was applied to show there was no binding between the 
BSA blocked electrode and the secondary Ab while the blank control demonstrated that the 
IDE did not display autofluorescence.  FITC-fluorescence was used to display average 
intensity values (obtained from image analysis software) with standard deviation error bars 
(for n=3 samples).   
 
3.3.4 Electrochemical characterization 
Potassium ferrocyanide, potassium ferricyanide, N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC), N-hydroxy succinimide (NHS) and ethanolamine, and FITC-
tagged anti-mouse secondary Ab were obtained from Sigma Aldrich. CIP2A Ag (0.063 
µg/µl) and mouse monoclonal Ab against CIP2A (0.5 mg/mL) were obtained from Origene 
Technologies, Inc (Rockville, MD). 2-(N-morpholino) ethanesulfonic acid (MES buffer, 0.5 
M, pH=6.0) was purchased from Fisher Scientific. Electrochemical characterization and 
sensing experiments were performed using a CHI6116E potentiostat (CH Instruments, 
Austin, TX). An Ag/AgCl reference electrode and Pt wire counter electrode from CH 
instruments, Inc within a ferricyanide solution (5 mM Fe(CN)6
3-/4-) were used for CV 
measurements. 
After functionalization with the CIP2A Ab, the VANTA IDEs were operated in a 2-
electrode set-up without the use of an external reference electrode and with an EIS sensing 
modality. CIP2A calibration curves were acquired by using the standard addition method 
(subsequent concentration of Ag was added to the same functionalized VANTA IDE) with 
EIS.  CIP2A sensing was carried out within 10 µL of PBS and 10 µL of human saliva 
supernatant. The healthy participant (without cancer) was required not to brush teeth, drink 
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hot liquids, or eat food in the morning before providing samples. 10 ml of whole saliva was 
collected by passive drool into a 15 ml plastic tube, and the supernatant was acquired by 
centrifuging the saliva at a speed of 1000 RPM for 30 min and then carefully removing the 
top of the liquid, viz., the supernatant, via pipette extraction from the solid phases. Finally, 
the supernatant was filtered by a 0.4 µm syringe filter. 
 
3.3.5 Raman spectroscopy 
Raman spectrum measurements of the VANTA IDEs were made using a Renishaw 
spectrometer with a 488 nm excitation source at a 20 mW laser power. A 20X objective lens 
was used in the microscope for data acquisition in the backscattered configuration. There 
were 5 acquisitions of 20 s each and the spectra were processed using R software (3.3.3.) to 
remove inherent fluorescence using a modified polynomial baseline reduction method.40 
 
3.4 Results and Discussion 
3.4.1 Fabrication and electrochemical characterization of VANTA IDE 
The VANTA IDEs were developed on silicon/silicon oxide wafers coated with an aluminum 
oxide (Al2O3) layer (Figure 3.1 & Experimental Section).  A thin (~ 7 nm) iron catalytic layer 
was patterned in an IDE arrangement (10 fingers per electrode with each finger measuring 1.95 
mm in length and 25 µm width and spacing) with two electrical probe pads on the wafer using 
physical vapor deposition (PVD) and ultraviolet (UV) photolithography (Figure 3.1b & c).   
The high-aspect-ratio VANTAs were subsequently grown on the IDE patterned iron layer 
using a chemical vapor deposition (CVD) method followed by an amorphous carbon 
infiltration process for structural support according to our previous work (Figure 3.1d).39,41 
The VANTA IDEs exhibited a height to width ratio of approximately 2 to 1 as the CNT height 
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measured approximately 50 – 80 µm.  After IDE fabrication, anti-CIP2A Ab was attached to 
the surface and used to capture CIP2A antigen (Ag) (Figure 3.1e). Prior to electrochemical 
sensing tests in the active solution, the electrical resistances of the two finger combs of the 
VANTA IDE were measured with 10-20  resistance across a contact pad (corner to corner).  
After a post-growth oxygen plasma etch, an infinitely high resistance between the two distinct 
finger combs was observed (i.e. no electrical shorting across the IDE fingers).  The general 
dimensions of VANTA IDEs are shown in Figure 3.1f, while the highly porous and defect-
rich nature of the VANTA structures was observed with field-effect scanning electron 
microscopy (FESEM) (Figure 3.1g&h). The high resolution FESEM images revealed 
individual nanotubes as well as the carbon matrix binding along the sidewall of the VANTAs. 
The entanglement of amorphous carbon and VANTAs resulted in mechanically stable 
structures during subsequent biofunctionalization and electrochemical sensing. Raman spectra 
revealed a G-band (~1590 cm-1), and 2D-band (~2700 cm-1), which correlates well with the 
spectra commonly associated with CNTs (Figure 3.1i).  Moreover, the presence of the D-band 
(~1350 cm-1) and its high intensity relative to the G-peak intensity (ID/IG~0.94) indicates a high 
quantity of superficial carbon defects.42,43 Such carbon defects are indicative of edge plane 
sites that have been shown to increase heterogeneous charge transfer during electrochemical 
sensing and deposition.44,45 
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Figure 3.1. Fabrication process steps of the VANTA IDEs. (a) PVD of 50 nm Al2O3 (purple) 
on a Si/SiO2 wafer (grey) followed by spin coated AZ1518 photoresist (red); (b) UV 
lithographic patterning of IDE footprint within the photoresist followed by PVD of a 7 nm 
thick iron (Fe) layer; (c) photoresist development and exposing Fe IDE pattern; (d) CVD 
growth of the VANTAs from the Fe pattern followed by in situ amorphous carbon infiltration; 
(e) schematic diagram showing anti-CIP2A Ab bound to the VANTA IDE with CIP2A Ag; (f) 
optical image showing the scale of a representative VANTA IDE next to a ruler (the numerical 
unit values on the ruler are in centimeters) (g) & (h) FESEM images of representative 
VANTAs from the IDE devices in both low and high magnification respectively; (i) Raman 
spectra of the VANTAs showing characteristic CNT D and G peaks. 
 
The electrochemical reactivity of the VANTA-IDEs was next characterized with both 
ferricyanide cyclic voltammetry (CV) and EIS (see Figure 3.2 and experimental section). 
Well-defined anodic and cathodic peak currents (Ip) were obtained across a range of scan rates 
(5, 10, 25, 50, and 100 mV s-1) due to the ferricyanide, Fe3+/Fe2+ redox couple (Figure 3.2a). 
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These peak currents display a linear relationship, indicating reversible behavior, when plotted 
against the square-root of the voltage scan (Randles-Sevcik plot) (Figure 3.2b).  Moreover, 
the peak-to-peak separation (ΔEp) values range from 0.10 V to 0.21 V across the acquired scan 
rates. Such low ΔEp values are indicative of fast and reversible heterogeneous electron charge 
transfer at room temperature and are significantly lower to ferricyanide electrochemistry 
electron transfer rates acquired from the basal planes of highly oriented pyrolytic graphite (ΔEp 
630 mV). The ΔEp values  compare favorably with similar CNT-based electrodes where 
aligned MWCNTs electrodes, horizontally oriented SWCNT paper, and vertically oriented 
SWCNT arrays report ΔEp values of 0.23 V, 0.096 mV, and 0.090 mV respectively.46–48 The 
effective electroactive surface area (A ≈ 0.00513 mm2) of the VANTAs was calculated by 
incorporating the recorded Ip values into the Randles-Sevcik equation (Eq. 1),  
I𝑝 = (2.69 ×  10
5)𝑛
3
2𝑣
1
2 𝐷
1
2 𝐶𝐴     (1) 
where n is the number of electrons transferred by the Fe3+/Fe2+ redox couple (n=1), v is the 
scan rate (v =100 mV/s), D is the diffusion coefficient (D = 7.20  10-6 cm2/s), and C is the 
analyte concentration (C = 5 mM).  An electroactive surface area of this value results in 
approximate 1% active sites (i.e., the surface area where heterogeneous charge transport 
occurs; active site is the ratio between electroactive surface area and geometric area) for the 
Fe3+/Fe2+ redox couple redox couple estimated during ferricyanide cyclic voltammetry (CV) 
at a scan rate of 50 mV/s.  Such values are greater than previous reports which demonstrate is 
greater than previous reports of 0.4% active sites.49 Thus, the porous nature of the VANTA 
IDEs significantly raises the electroactive surface area above a conventional solid or planar 
IDE sensor50 and provides more carbon-carbon defects or active sites than conventional CNT 
electrodes.51,52 
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To further demonstrate the impedimetric response of the VANTA IDEs, EIS 
ferricyanide measurements were conducted in the frequency range from 0.1 Hz to 1 MHz using 
increased concentrations of KCl (from 1.0 µM to 1.0 M KCl) (Figure 3.2d-e). These faradaic 
EIS measurements can be represented as a three component equivalent circuit (i.e., a 3 
electrode potentiometric set-up with a reference electrode—the sensing modality used to 
electrochemically characterize the VANTA IDEs) where Cdl is the double layer capacitance, 
Rs is ionic resistance from electrolyte , and Cdi is the dielectric capacitance from the 
electrolyte.53 At lower frequencies (0.1 Hz to 10 Hz), Cdl governs the overall impedance 
change, from which lower KCl concentration leads to a higher amplitude and lower phase shift. 
At the intermediate frequency region (10 Hz to 10 KHz), the conduction/resistance of ions in 
solution, Rsol, dominates the impedance.  At higher frequencies (10 KHz to 1 MHz), the 
dielectric capacitance supersedes the impedance, resulting in a higher phase shift at lower KCl 
concentrations.53 These results (Figure 3.2d & e)) indicate how each component of VANTA 
IDEs respond to the change of KCl concentrations in the electrolyte. In addition, the VANTA 
IDEs displayed increased sensitivity to KCl concentrations changes as compared to 
conventional 2D planar IDEs under similar conditions (Figure 3.2f),50 corroborating the high 
sensitivity of the VANTA IDEs in subsequent immunosensing.  
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Figure 3.2. Electrochemical testing of VANTA IDE devices: (a) Cyclic voltammetry (CV) at 
scan rates of 10, 25, 50, 75, and 100 mV/s; (b) Current density vs. the square root of the scan 
rate; (c, d, e) VANTA IDEs are characterized by sensing various concentrations of KCl, and 
the resulting (c) Nyquist plots, (d) impedance, and (e) phase change vs. frequency were plotted 
as well as (f) Cdl and phase shift at 100 KHz versus KCl concentration.  
 
3.4.2 Biological characterization of VANTA IDE 
Prior to immunosensing, immobilization of the anti-CIP2A Ab onto the VANTA IDEs 
was confirmed via fluorescence imaging (Figure 3.3).  To visualize the successful loading of 
Ab (see experimental section), a fluorescein isothiocyante (FITC) -tagged, secondary Ab was 
used to bind the primary Ab, thus relating fluorescence to the amount of anti-CIP2A Ab on the 
VANTA IDE surface (positive control). To evaluate non-specific binding of the FITC-tagged 
Ab with the VANTA IDE surface, a negative control was performed in which the FITC-tagged 
Ab was incubated with the VANTA IDEs in the absence of primary Ab surface 
functionalization.  The negative control experiment resulted in negligible VANTA fluorescent 
labeling (Figure 3.3a) as compared to the positive control.  The positive control experiment 
did result in measurable VANTA fluorescence labeling (Figure 3.3b). Results for the positive 
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and negative Ab loading experiments are compiled in Figure 3.3c where a histogram compares 
the FITC-fluorescence intensities (%) of the negative and positive controls to samples without 
any biofunctionalization. The result proves the successful loading of Abs onto the surface of 
VANTA IDEs. 
 
Figure 3.3. Fluorescence monitoring of Ab-Ag binding to the VANTA IDEs. (a) Fluorescence 
emitted from the VANTA IDEs functionalized with FITC-tagged secondary Ab only 
(fluorescence OFF), and (b) with both primary CIP2A antibodies and FITC tagged secondary 
antibodies (fluorescence ON) (c) Comparative histogram depicting the fluorescence emission 
from the blank, negative control, and positive control VANTA IDEs respectively (n = 3). 
 
3.4.3 Immunosensing of CIP2A in PBS and saliva 
To perform immunosensing of CIP2A (Figure 3.4.3), the VANTA IDEs were 
functionalized with anti-CIP2A Ab and then incubated with increasing concentrations of 
CIP2A Ag. EIS measurements revealed that the immunosensor was capable of sensing CIP2A 
across a wide concentration range from 5 pg/mL to 400 pg/mL in phosphate buffer solution 
(PBS; see calibration plots in Figure 3.4a) and from 1-100 pg/ml in saliva supernatant (Figure 
3.4a, see Experimental Section). Figure 3.4b presents the Nyquist plot of impedance 
measurements for the detection of CIP2A in saliva supernatant. It should be noted that the 
magnitude of each Nyquist plot (i.e., the radius of the first half circle, Figure 3.4b) increases 
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with increasing CIP2A concentration.  The normalized percent change of charge transfer 
resistance, Rct, was calculated and plotted versus concentrations of CIP2A (Figure 3.4a,c,d). 
The linear CIP2A sensing range of the VANTA IDE immunosensor (5-400 pg/ml in PBS and 
1-100 pg/ml in saliva) was calculated using linear regression analysis of the normalized charge 
transfer resistance versus the functionalized CIP2A concentration plots. The gray shaded area 
in the plot (Figure 3.4a) indicates the sensing range of a typical human CIP2A ELISA kit 
(0.156-10 ng/mL)54; the VANTA IDE sensing platform demonstrates higher sensitivity and a 
Figure 3.4. CIP2A sensing with VANTA IDEs. (a) Functionalized VANTA IDEs were tested 
in saliva and PBS with CIP2A concentration ranging from 0.1 pg/ml to750 pg/ml. The first 
data points are acquired as a baseline without CIP2A. Grey shaded region shows the sensing 
range of a typical human CIP2A ELISA kit. (b) Nyquist plots of detection of CIP2A in saliva 
supernatant. (c) Calibration plots of CIP2A Ab functionalized VANTA IDEs tested in saliva. 
The linear sensing range (red) is between 1 and 100 pg/ml. (d) Functionalized electrodes were 
also tested in saliva with increased incubation times and increased BSA concentrations, 
indicating stationary impedance readings.  
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lower sensing range in both PBS and saliva supernatants than ELISA. Functionalized VANTA 
IDEs were also tested in saliva with increased incubation times (30, 45, 60, 90, and 120 mins) 
and increased BSA concentrations (0.5%, 1% and 2%), from which the impedance 
measurements indicated minimal interference and high stability in the complicated biological 
environment (see Figure 3.4d). This implies the feasibility of applying VANTA IDEs toward 
early stage detection of oral cancers. 
 
3.4.4 Statistical analysis and model fitting 
To better explain the difference in range of sensing activity between the two sample 
mediums, the calibration curves for CIP2A detection in saliva and PBS were both fit using 
non-linear regression analysis using the Hill Equation (see Supplemental Information - Figure 
S1).  This sigmoidal curve fit indicates the biosensor performance characteristics and enables 
a better understanding of the binding activity between Ab and Ag within different 
environments.55–57  The dissociation constant (KD), or Ab affinity to Ag, was calculated for the 
biosensor operating in both saliva and PBS via the Hill Equation (see Methods). The PBS 
sensing data resulted in a KD value of 82 pg/ml with a Hill coefficient of 0.98 (or ~ 1 which is 
indicative of independent binding).  However, in saliva the KD value was determined to be 13 
pg/ml (higher Ab affinity to Ag than in PBS) with a Hill coefficient of 1.62 (indicative of slight 
positive cooperative binding).  The primary governing factors that control Ab-Ag binding 
within an aqueous medium are the pH, salt type, temperature, and ionic strength of said 
medium.58,59 In the case of this reported VANTA IDE, the decreased KD value or increased 
antibody affinity to CIP2A Ag and higher level of cooperative binding displayed during 
biosensing in the saliva supernatant matrix was likely a result of a more optimal pH, salt type, 
and ionic strength in the saliva solution than in PBS.  It is also worth noting that saliva 
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supernatant was used in these experiments so that non-specific absorption from high molecular 
weight proteins and cellular matter (which could reduce biosensor sensitivity) was minimized 
as these particles were removed during the centrifugation process.60 The biosensor detection 
limit was estimated from the linear portion of the Hill Equation calibration fit (note the 
calibration fit includes an initial stationary stage, linear sensing stage, and saturation stage – 
Figure S1).  Subsequently the CIP2A detection limit in both PBS and saliva, 4.69 pg/mL and 
0.24 pg/ml respectively, were acquired from the intersection between the linear trend line of 
the Hill Equation calibration fit and the x-axis (using 3 times the standard deviation of the 
stationary stage before linear sensing range or 3σ guidelines). (Figure 3.4a, c). 
The electrical/electrochemical behavior of the VANTA IDE immunosensors was 
further evaluated using an equivalent circuit model based on previous reports for IDEs operated 
in a faradaic EIS sensing modality (i.e., a 2-electrode potentiometric set-up without a reference 
electrode—the sensing modality used herein for immunosensing).31 The equivalent circuit 
model was created for the VANTA IDE biosensors by connecting two constant-phase-elements 
in parallel with a resister (CPE-R) in series with Rs (i.e., bulk solution ionic resistance 
according to Randles model38) (Figure S2). Since the VANTAs are comprised of a porous 
material, two semicircle patterns are observed in the Nyquist plot,61,62 which correspond to two 
CPEs from the equivalent circuit simulation. The parallel combination of CPE1 and R1 
indicates the geometric capacitance of the IDE sensor and the charge transfer resistance of the 
film layer. The CPE2 and R2 components represent the capacitance and resistance at the 
interface between the film and the solution.63 Figure S2 presents a comparison of the 
experimental impedance (Nyquist plot) and simulated result using the circuit model for 0.1 
pg/mL of concentration of Ab functionalization, clearly demonstrating close similarity. 
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VANTA IDEs exhibit an Rs of 100 Ω, R2 of 2000 Ω and R3 of 1100 Ω, while CPE1 and CPE2 
have n values of 0.95 and 0.80 respectively, indicating CPE1 acts more like a capacitor while 
CPE2 is more like a resistor. Fitting experimental data to the equivalent circuit reveals how 
each component behaves electrically in the electrolyte and changes with the increase of CIP2A 
concentration. In addition, it proves that the charge transfer resistance was responsible for the 
detection of CIP2A. 
3.5 Conclusion 
In conclusion, this work demonstrated the first use of VANTA IDEs for electrochemical 
biosensing of CIP2A. It builds upon the recent body of research that has demonstrated the use 
of VANTA interdigitated structures for a wide variety of applications including flexible 
capacitive sensors for wearable strain and force monitoring,64 solid-state micro capacitors,65,66 
and electrostatic torsional actuators.67 The VANTA IDEs developed herein were functionalized 
with anti-CIP2A Ab and demonstrated a wide linear sensing range between 5 pg/mL and 400 
pg/mL, in buffer with a detection limit of 4.69 pg/mL for CIP2A Ag, a key diagnostic 
biomarker expressed in saliva during the early stages of oral cancer.  Moreover, the sensor 
demonstrated the capability of detecting CIP2A in saliva supernatant with a sensing range of 
1-100 pg/ml and detection limit of 0.24 pg/ml without the need for sample pre-labeling or pre-
concentration techniques. This detection limit and sensing range is much lower than the 
detection range (0.156 ng-10 ng/ml) reported for commercial human CIP2A ELISA kits.54 
Moreover, the total sensing time required for this biosensor is less than 35 minutes (including 
sample incubation and signal acquisition time).  Hence, this work demonstrates great promise 
in providing a potential platform technology for oral cancer detection at the POC and/or 
potential for detecting other Ags in a saliva matrix.  Moreover, CIP2A production is also linked 
to other cancers such as breast and melanoma cancers, and therefore the VANTA IDEs 
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developed herein could conceivably be modified for use in the blood or tissue matrix for 
multiple cancer screening experiments. 
Indeed, this work not only paves the way for the exploitation of VANTA IDE devices 
as immunosensors, but also for electrochemical biosensing in general. The 3D VANTA 
structures were conducive to Ab biofunctionalization and did not interfere with immunological 
binding motifs while still providing gaps in the biorecognition layer for significant charge 
transfer to occur during EIS measurements.  Hence the VANTA-IDEs enable Ag detection 
without the need for secondary Ab/nanoparticle labels.  Furthermore, the use of faradaic EIS 
performed with the redox probe [Fe(CN)6]3−/4− eliminated the need for a reference electrode 
or a 3-electrode electrochemical set-up.15  The elimination of 3-electrode patterning and a 
redox material makes these VANTA-IDEs well-suited for miniaturization, large scale 
fabrication and potential incorporation into microfluidic channels for multiplex 
electrochemical sensing of a wide variety of target analytes from a single sample.  Moreover, 
the use of electrochemical devices enables POC sensing as only minimal equipment such as a 
portable potentiostat (similar to a glucometer) can be used by non-technical staff to operate the 
screening tests. Hence electrochemical devices can circumvent the challenges associated with 
fluorescence/optical based sensors that require complex equipment/processes (e.g., 
fluorescence microscopes, pre-labeling steps) and that can be impeded by turbid, optically 
dense or autofluorescent biological samples.68 Furthermore, the fabrication protocol for 3D 
CNT electrodes developed herein could be applied to emerging fields that have incorporated 
CNTs into numerous electrochemical applications including sensors, fuel cells, actuators, and 
energy harvesters.69–71  
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3.6 Supplemental Information 
The high-aspect-ratio VANTA IDE devices (typically consisting of multi-walled 
CNTs grown with average diameter of 20-30 nm and height of 50-80 µm) are synthesized 
using a chemical vapor deposition (CVD) process. First, a silicon wafer with a 300 nm thick, 
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thermally grown oxide was used as a base substrate for the device fabrication. An e-beam 
deposited Al2O3 film of 50 nm thickness is deposited onto the wafer using a Denton e-beam 
evaporator (Figure 3.1a). With an AZ3330 resist coating, the IDE pattern was defined by 
photolithography, and resist development (Figure 3.1b). A 7 nm iron layer is thermally 
evaporated onto the wafer, followed by photoresist lift off using N-Methyl-2-pyrrolidone for 
10 min, leaving the IDE-patterned iron catalyst ready for CNT growth (Figure 3.1c). A 
Lindberg/Blue M tube furnace was used for CNT growth using controlled flow of hydrogen 
(311 sccm) and ethylene (338 sccm) at 750 °C for 30 seconds (Figure 3.1d). To ensure 
mechanically robust yet porous arrays of IDE fingers, in-situ amorphous carbon infiltration 
into the CNT forest was made for 3 min by flowing hydrogen and ethylene (311 sccm and 
193 sccm, respectively) at 900°C (Figure 3.1d).39  In order to remove the carbon floor 
between the fingers of the IDE, which is deposited in a conformal fashion across the entire 
IDE and silicon wafer surface during the deposition of the amorphous carbon, an oxygen 
(O2) plasma etch was performed using a Technics Planar Etch II for 45 s at 250 W and 300 
mTorr. 
The activity of the Ag and Ab pair, were tested prior to functionalizing electrodes, 
using immunoblotting. VANTA IDEs were cleaned in 0.1 M MES buffer for 10 mins, 
followed by incubation in a solution of 0.4 M EDC and 0.1 M NHS prepared in 0.1 M MES 
buffer for 1 h. The VANTA IDEs were washed in PBS and then placed under a gentle stream 
of nitrogen gas to remove excess amount of liquid that did not dry out or damage the surface 
chemistry. Next, the VANTA IDEs were incubated overnight with a 1:100 (5 µg/mL) 
dilution of CIP2A Ab.  The reaction was quenched with 1.0 M ethanolamine to block 
unbound carboxyl groups. Finally, the IDEs were blocked in 2% BSA for 1 h to reduce non-
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specific binding of the Ag to bare areas of the electrode or substrate during electrochemical 
sensing. The functionalized electrodes were washed in PBS and placed under a nitrogen 
stream that was sufficiently strong to remove excess water but sufficiently weak to leave the 
biofunctionalized surface unharmed as verified with subsequent fluorescence microscopy and 
electrochemical CIP2A biosensing. For sensing CIP2A, 20 µL of Ag (at indicated 
concentrations) was placed on the IDE and incubated for 30 min. EIS measurements were 
performed in 5 mM ferro/ferricyanide solution (Figure 3.4).  
The amine terminated CIP2A antibody has an approximate size of 102 kDa and is 
covalently bound to the superficial carboxyl groups found on the CNT surface via EDC/NHS 
chemistry.  Hence the immobilized antibody extends approximately 3 nm outward from the 
surface of the CNTs . To put these dimensions into perspective, the carbon coated CNTs 
within the VANTA IDEs have an approximate width of 100 nms while the width of one the 
IDE fingers is 25 µm. 
Three VANTA IDEs were prepared for fluorescence spectroscopy measurements as 
follows: the first positive control electrode was biofunctionalized using the protocol written 
in the Functionalization Chemistry section; the second negative control electrode was 
prepared in a similar fashion but without the use of primary Ab; while the third electrode was 
a non-functionalized bare IDE (control). Next, 10 µL of 1:200 dilution of anti-mouse IgG-
FITC Ab produced in goat were placed on positive and negative controlled IDEs respectively 
and incubated for 1 h. The negative control was applied to show there was no binding 
between the BSA blocked electrode and the secondary Ab while the blank control 
demonstrated that the IDE did not display autofluorescence.  FITC-fluorescence was used to 
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display average intensity values (obtained from image analysis software) with standard 
deviation error bars (for n=3 samples).   
Potassium ferrocyanide, potassium ferricyanide, N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC), N-hydroxy succinimide (NHS) and ethanolamine, and FITC-
tagged anti-mouse secondary Ab were obtained from Sigma Aldrich. CIP2A Ag (0.063 
µg/µl) and mouse monoclonal Ab against CIP2A (0.5 mg/mL) were obtained from Origene 
Technologies, Inc (Rockville, MD). 2-(N-morpholino) ethanesulfonic acid (MES buffer, 0.5 
M, pH=6.0) was purchased from Fisher Scientific. Electrochemical characterization and 
sensing experiments were performed using a CHI6116E potentiostat (CH Instruments, 
Austin, TX). An Ag/AgCl reference electrode and Pt wire counter electrode from CH 
instruments, Inc within a ferricyanide solution (5 mM Fe(CN)6
3-/4-) were used for CV 
measurements. 
After functionalization with the CIP2A Ab, the VANTA IDEs were operated in a 2-
electrode set-up without the use of an external reference electrode and with an EIS sensing 
modality. CIP2A calibration curves were acquired by using the standard addition method 
(subsequent concentration of Ag was added to the same functionalized VANTA IDE) with 
EIS.  CIP2A sensing was carried out within 10 µL of PBS and 10 µL of human saliva 
supernatant. The healthy participant (without cancer) was required not to brush teeth, drink 
hot liquids, or eat food in the morning before providing samples. Whole saliva (10 ml) was 
collected by passive human drool into a 15 ml plastic tube, and the supernatant was acquired 
by centrifuging the saliva at a speed of 1000 RPM for 30 min and then carefully removing 
the top of the liquid, viz., the supernatant, via pipette extraction from the solid phases. 
Finally, the supernatant was filtered by a 0.4 µm syringe filter. 
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Raman spectrum measurements of the VANTA IDEs were made using a Renishaw 
spectrometer with a 488 nm excitation source at a 20 mW laser power. A 20X objective lens 
was used in the microscope for data acquisition in the backscattered configuration. There 
were 5 acquisitions of 20 s each and the spectra were processed using R software (3.3.3.) to 
remove inherent fluorescence using a modified polynomial baseline reduction method.40 
 
Figure S1. (a). The calibration curve of the CIP2A sensing (in Saliva) was fit using Hill’s 
equation, which shows the estimated KD value is 13 pg/ml with a coefficient of 1.62.  (b). 
The calibration curve of the CIP2A sensing (in PBS) is fitted by Hill’s equation, and the 
resulting KD value is 82 pg/ml with a coefficient of 0.98. 
 
The data was fitted by non-linear regression using the Hill Equation, and the linear 
region was utilized to acquire detection limits using 3σ guidelines (Figure S1).  The resultant 
curve fit equations are given below where  𝜃 is the fraction of occupied Ab that Ag can 
potentially bind to, Ag is the concentration of Ag, and KD is the dissociation constant. 
𝜃(𝑖𝑛 𝑃𝐵𝑆) =
𝐴𝑔0.98
𝐾𝐷 + 𝐴𝑔0.98
 
𝜃(𝑖𝑛 𝑠𝑎𝑙𝑖𝑣𝑎) =
𝐴𝑔1.62
𝐾𝐷 + 𝐴𝑔1.62
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Figure S2. (a). Experimental Nyquist plot of the VANTA IDE (black) fitted with the 
simulated equivalent circuit model result (red), and (b) equivalent circuit model of the 
VANTA IDEs. 
 
 
Figure S3. Static water contact angle measurement showing a 1 ul water droplet resting on 
top of the a VANTA IDE. The measured contact angle was ~ 69.2º.  Note the black lines in 
the focal plane of the image are the VANTA IDEs while the reflection of the droplet can be 
viewed in the foreground of the image. 
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CHAPTER 4.    DETECTION OF IFN- AND IL-10 THROUGH VERTICALLY-
ALIGNED CARBON NANOTUBE INTERDIGITATED ELECTRODES TOWARD 
IMPANTABLE CATTLE PARATUBERCULOSIS 
4.1 Abstract  
3D vertically aligned carbon nanotube array (VANTA) is featured with increased 
surface area, high aspect ratio, chemical inertness, superior electrical conductivity, which is 
deemed as an appealing candidate for biosensing material. Herein we report the first VANTA 
interdigitated electrode (IDE) array for electrochemical biosensing of IL-10 and IFN-. The 
VANTA-IDE was functionalized with antibodies (Abs) specific to IL-10 and IFN- that are 
early stage biomarkers to the Johnnes’s disease (Bovine Paratuberculosis). The resultant 
immunosensor is capable of detecting IL-10 and IFN- rapid (<35 mins) and label-free across 
wide linear sensing ranges (0.1 -100 pg/ml and 0.1 to 50 pg/ml, respectively) and low detection 
limits (0.054 pg/ml and 0.099 pg/ml) in PBS buffer.  Moreover, the VANTA-IDE showed great 
promise in sensing in actual biological fluid as the biosensor was able to sense IL-10 and IFN-
 within diluted bovine implant supernatant over concentration ranges of 0.1 to 30 pg/ml 
(detection limit:0.077 pg/ml) and 50-1000 pg/ml (detection limit :95.87 pg/ml), respectively. 
These results help pave the way for rapid disease screening tests at the point-of-care (POC) 
such as for the early-stage diagnosis of Johnne’s disease.      
 
4.2 Introduction 
There is a critical need for development of an accurate diagnostic test for identification 
of animals in the early stages of Mycobacterium Avium subspecies Paratuberculosis (MAP) 
infection (termed “stage I”).1 Detection of stage I infected animals is a priority because, based 
on current tests, they have no identified serological markers of disease; are not shedding the 
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pathogen in feces; and have no detectable clinical signs. Stage I animals contribute directly to 
spread of infection throughout the herd. This is because they will progress to bacterial shedding 
before they are identified. Therefore, the lack of accurate diagnostic tools for this category of 
Map infected animals is a substantial problem that severely impacts our ability to control 
spread of Bovine Paratuberculosis (Johne’s disease) in the livestock industry. Current 
diagnostic assays for Johne’s disease are generally based on three strategies: identification of 
the bacterium, identification of circulating antibody, or detection of cellular immunity. Both 
development of circulating antibody and shedding of the bacterium are associated with late 
(clinical disease) and these animals are already a source of infection to naïve calves. Because 
the cell mediated immune responses develops early after MAP infection and is maintained 
during the subclinical period detection of cell mediated immunity is the best-suited approaches 
for identification of cattle in the early stages of MAP infection, especially stage I infected 
cattle. Currently available methods are based on detection of cytokine from ex vivo stimulated 
peripheral blood cells or measuring skin swelling in response to injected mycobacterial 
antigens.2,3 However, as they exist today these assays will also detect animals exposed to 
closely related environmental species of mycobacteria and vaccinated animals, thus these 
assays lack specificity.4 Moreover, the ex vivo assay requires that blood is drawn and shipped 
to a lab where leukocytes are stimulated ex vivo and cytokines measured. The lag time and 
artificial culture conditions of the assay are another source of error and variability in the assay. 
Currently detection of cell-mediated immune responses is not in widespread use in the field 
for diagnosis of MAP infection cattle.  
Measurement of interferon gamma (IFN-γ) from stimulated blood leukocytes is a 
validated diagnostic assay for detection of tuberculosis in humans and cattle. Recently there 
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has been growing interest in using multiplexed cytokine detection approaches for diagnosis 
of mycobacterial diseases. It has recently been shown that evaluation of multiple cytokines 
rather than a single cytokine parameter enhances accuracy of these assays, as well as 
providing important biomarkers of disease progression.5 Specifically a ratio between IFN-γ 
and IL10 has been successfully used for diagnosis and prediction of disease outcomes in 
humans with tuberculosis.6 Both IFN-γ and IL-10 have been identified as a cytokine 
components of the early immune response to MAP，which makes measuring both IFN-γ and 
IL-10 an accurate measure of early infection with MAP in cattle.7 The collaborator group led 
by Dr. Hostetter from veterinary medicine school at Iowa State University has detected both 
of these cytokines in calves that have been vaccinated for MAP. Vaccination for MAP leads 
to strong cell mediated immune responses.  They have also measured IFN-γ and IL-10 in 
cattle naturally infected with MAP.  However, there currently does not exist an in-field assay 
that can detect Johnne’s Disease in young cattle. 
Conventional laboratory techniques include, using a sandwich enzyme-linked 
immunosorbent assay (ELISA), enzyme-linked immunospot assay (ELISPOT), or reverse 
transcriptase polymerase chain reaction (RT-PCR) to monitor IFN-γ and IL-10 in various 
biological solutions.7–11  Though these techniques can detect IFN-γ (e.g., 5–10 pg/mL for 
tuberculosis,12 15 pg/mL for HIV,13 and 7.4 pg/mL for Crohn’s disease14), and IL-10 (e.g., 
1.0 - 23.9 pg/ml for Systemic lupus erythematosus15, 1062±253 pg/ml for atopic dermatitis 
11, 20 pg/ml  for acute Graft-vs-host- disease, 10 and 45.3±7.8 and 18.0±2.3 pg/ml for Asthma 
or Chronic Obstructive Pulmonary disease, respectively) at biologically relevant 
concentrations, they have common drawbacks such as a long detection time, extensive 
65 
 
sample handling, manipulation of the cytokine and requirement of expensive and/or bulky 
equipment.16  
Besides these conventional laboratory methods, a plethora of non-commercial 
techniques for IFN-γ and IL-10 have been developed including field effect transistor based 
biosensors (Bio-FETs)17,18, Förster resonance energy transfer (FRET) aptamer beacons19–23, 
flow cytometry24  and Localized surface plasmon resonance (SPR)-based microfluidic optical 
biosensing.22 These reported biosensing techniques display tremendous promise toward 
sensitive and rapid IFN-γ and IL-10 sensing with detection limits extending down into the 
nanomolar and even picomolar regimes. However, one of the drawbacks for Bio-FET is that 
it is difficult to monitor protein-protein binding process, since recognition might occur 
outside the electrical double-layer associated with the fate, causing small potential changes 
on the gate.25 In addition to that, Bio-FET and SPR sensing would require more intensive 
clean room manufacturing steps that substantially increase the cost of biosensor and hinder 
the possibility of large-scale fabrication.26  In terms of FRET based biosensing, it presents 
several disadvantages such as the requirement of monochromatic light, photobleaching 
induced by the donor fluorophore that results in loss of signal with time, and the background 
always suffer from autofluorescence emitted by endogenous cell components.27While SPR 
based sensing mostly require signal amplifications, suffering from non-specific absorption 
and low bioactivity of the immobilized biomolecules due to immobilization schemes.28 As 
for flow cytometry, it can analyze the presence and reporter intensity of thousands of 
individual cells per second 29 and its informative richness facilitates statistical and numerical 
treatment of the data,30 however, this technique is strictly limited to ex situ measurements, 
sophisticated equipment, expensive costs and complicated operations.31  Finally, it has to be 
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noted that all of the above mentioned methods requires laboratory setting (control 
experiments must be meticulously designed) as well as expensive instrumentation, which is 
also unrealistic toward in-field application.9,25,28,32 
Electrochemical impedance-based biosensors circumvent these challenges by offering 
relatively facile fabrication procedures, label-free operation, and rapid (<35 min) in-field 
sensing.21,33,34 Currently reported IL-10 could reach detection range of 1-15 pg/ml and 0.1-20 
pg/ml.18,35,36 While IFN-γ  biosensors were reported to cover sensing range of 1-5 ng/ml 9 
and  0.0001 to 0.1 ng/ml 37. Most of these biosensor studies would only focus on one kind of 
cytokine level with various sensing ranges; study target was mostly human or require 
labeling for signal amplification purpose, while this project specifically targets for Johnne’s 
disease and its two major cytokines. In addition, this multiplex biosensor will be evaluated in 
the unique biological environment- the actual bovine implant. Consequently, all the 
presented sensing protocol and the study about multiplex biosensing toward bovine 
paratuberculosis will increase the likelihood of POC testing. In particular, electrochemical 
impedance-based biosensors based on interdigitated electrodes (IDEs) experience 
advantageous mass transport and reaction kinetics effects (nonplanar or radial diffusion to 
each individual microband or IDE finger), higher current densities (electrical field lines are 
concentrated around tightly packed microbands), and favorable Faradaic-to-capacitive 
current ratios that lead to improved biosensor signal-to-noise ratios and hence higher 
sensitivity and lower detection limits for enhanced detection of antibody–antigen or aptamer–
target binding events.9,38–40 
Herein we report the first 3D VANTA impedemetric immunosensor for the detection 
of IL-10 and IFN- that are early stage biomarkers for bovine Paratuberculosis. VANTA 
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IDEs, fabricated with 40 microbands with width of 25 µm, were functionalized with Abs 
specific to bovine IL-10 and IFN-, and tested in PBS buffer as well as diluted cattle implant 
serum. The results demonstrate great sensitivity, robustness and selectivity, which proves the 
feasibility of POC diagnosis for bovine paratuberculosis. 
4.3 Material and Methods 
 
4.3.1 VANTA IDE fabrication  
The fabrication of the high-aspect ratio VANTA IDE devices started with the growth 
of the nanotubes using a chemical vapor deposition process. One silicon wafer with a 300 nm 
thick, thermally grown oxide was utilized as a base substrate, and an e-beam deposited Al2O3 
film of 50 nm thickness was deposited onto the wafer using a Denton e-beam evaporator.  AZ 
3330 resist coating and a IDE pattern of 40 fingers and 25 µm spacing/width were then defined 
by photolithography and resist development. This device was fabricated by the bottom up 
method and 7 nm iron layer was thermally evaporated onto the base substrate. It was then 
followed by photoresist lift off using N-Methyl-2-pyrrolidone for 10 min, leaving the IDE-
patterned iron catalyst ready for CNT growth. In order to control the CNT growth, a 
Lindberg/Blue M tube furnace was used  to maintain controlled flow of hydrogen (311 sccm) 
and ethylene (338 sccm) at 750 °C for 30 seconds. Since this device needs to withstand long 
time sensing and fabrication processes, the mechanical robustness yet porous structure was 
ensured by in-situ amorphous carbon infiltration into the CNT forest, which was accomplished 
by flowing hydrogen and ethylene (311 sccm and 193 sccm, respectively) at 900°C for 3 
mins.41 Finally, the carbon floor from previous step between the electrodes of the IDE was 
removed by an oxygen plasma etching, which was performed using a Technics Planar Etch II 
for 45 s at 250 W and 300 mTorr. 
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4.3.2 Electrochemical characterization 
Potassium ferrocyanide, potassium ferricyanide, N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC), N-hydroxy succinimide (NHS) and ethanolamine, and FITC-
tagged anti-mouse secondary Abs were obtained from Sigma Aldrich. Mouse anti Bovine IL-
10 and IFN- Abs and Bovine Ags were obtained from Bio-rad. 2-(N-morpholino) 
ethanesulfonic acid (MES buffer, 0.5 M, pH=6.0) was purchased from Fisher Scientific. 
Electrochemical characterization and sensing experiments were performed using a 
CHI6116E potentiostat (CH Instruments, Austin, TX). An Ag/AgCl reference electrode and 
Pt wire counter electrode from CH instruments, Inc within a ferricyanide solution (5 mM 
Fe(CN)6
3-/4-) were used for cyclic voltammetry (CV) characterization. 
After functionalization with the IL-10 or IFN-gamma Abs, the VANTA IDEs were 
operated in a 2-electrode set-up. Since anodic and cathodic electrodes are closely packed 
together, minute amounts of ionic species can be efficiently (>0.98) cycled between the 
electrodes.42 Consequently, IDE eliminates the need for a reference electrode and provides 
simple means for obtaining a steady state current response, especially compared to three and 
four electrode set-up,43 which also allows large scale fabrication. Calibration curves were 
acquired by using the standard addition method (subsequent concentration of Ag was added 
to the same functionalized VANTA IDE) with EIS, the setting of which was 0.1 to 1 MHz 
with an AC amplitude of 5 mV.  IL-10 and IFN- sensing were carried out within 10 µL of 
PBS and 10 µL of 1:1000 ratio diluted cattle implant supernatant. The supernatant was 
acquired by centrifuging the minced implant at a speed of 1000 RPM for 10 mins and then 
carefully removing the top of the liquid, viz., the supernatant, via pipette extraction from the 
solid phases. The cattle implant was received through the process as seen in Figure.4.1. This 
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implant environment had collagen that allows infiltration of immune cells and protein but 
still retain its stable environment in the implant housing. 
 
 
Figure 4.1. (c) is an image of the implant and the devices used for placing the implant in 
subcutis. The implant consists of an outer 4 cm×0.5 cm stainless steel housing that has a single 
3 cm× 0.3 mm window (a). A 2cm solid pin was attached to one end of the implant that is used 
for removing the implant from the subcutis (Fig a, red arrow). The housing immediately 
surrounds a nylon mesh that has a pore size of 30 microns, which was exposed to the exterior 
along the window in the housing (Fig b). The nylon mesh surrounds a core of bovine purified 
collagen (PureCol, Advanced Biomatrix, Iowa City IA.). (d)The implant was then minced and 
centrifuged to acquire supernatant. (e&f) Functionalized VANTA IDEs were tested with 
spiked concentrations of Ags in diluted supernatant. 
 
 
 
4.3.3 Functionalization chemistry 
The activity of the Ag and Ab pair, were tested prior to functionalizing electrodes, 
using immunoblotting. VANTA IDEs were cleaned in 0.1 M MES buffer for 10 mins, 
followed by incubation in a solution of 0.4 M EDC and 0.1 M NHS prepared in 0.1 M MES 
buffer for 1 hr.  Devices were then washed in PBS, dried with nitrogen gas to remove excess 
amount of liquid, and incubated overnight with a 1:50 dilution (20 µg/mL) of IL-10 and IFN-
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 Abs. The reaction was quenched with 1.0 M ethanolamine for 20 mins to quench unbound 
carboxyl groups. Finally, the IDEs were blocked in 2% BSA for 1 hour to reduce non-
specific binding of the Ag to bare areas of the electrode or substrate during electrochemical 
sensing. The functionalized electrodes were washed in PBS and blown with nitrogen gas. For 
sensing test, 20 µL of Ag (at indicated concentrations) was placed on the IDE and incubated 
for 30 min. EIS measurements were performed in 5 mM Fe(CN)6
3-/4-) PBS buffer solution. 
 
4.3.4 Fluorescence tagging 
Two VANTA IDEs were prepared for fluorescence spectroscopy measurements as 
follows: the first positive control electrode was biofunctionalized using the protocol written in 
the Functionalization Chemistry section; the second negative control electrode was prepared 
in a similar fashion but without the use of primary Ab. Next, 10 µL of 1:100 dilution of anti-
mouse IgG-FITC Ab produced in goat were placed on positive and negative controlled IDEs 
respectively and incubated for 1 hr. The negative control was applied to show there was no 
binding between the BSA blocked electrode and the secondary Ab.  
 
4.4 Results 
 
Ferrycyanide CV and non-faradic impedance spectroscopy sensing in KCl were then 
utilized to characterize the electrochemical reactivity of the VANTA-IDEs. Well-defined 
anodic and cathodic peak currents (Ip) were obtained across a range of scan rates (5, 10, 25, 
50, and 100 mV s-1) due to the ferricyanide, Fe3+/Fe2+ redox couple (Figure 4.2a). The linear 
relationship between peak currents and the square root of the voltage scan rate demonstrated 
from Randles-Sevcik plot in Figure 4.2b showed reversible behavior, indicating the process 
71 
 
was unequivocally controlled by the diffusion of species in solution. Moreover, the peak-to-
peak separation (ΔEp) values range from 0.12 V to 0.32 V with formal potential of 0.24 V ~ 
0.26 V across the acquired scan rates.  
Such ΔEp values are indicative of fast and quasi-reversible one electro transfer process 
at room temperature and are significantly lower to ferricyanide electrochemistry electron 
transfer rates acquired from the basal planes of highly oriented pyrolytic graphite (ΔEp 630 
mV). The ΔEp values compare favorably with similar CNT-based electrodes where aligned 
MWCNTs electrodes, horizontally oriented SWCNT paper, and vertically oriented SWCNT 
arrays report ΔEp values of 0.23 V, 0.096 V, and 0.090 V respectively.44–46 The effective 
electroactive surface area (geometric area ≈ 0.0099 cm2, A= 0.000089 cm2) of the VANTAs 
was calculated by incorporating the recorded Ip values into the Randles-Sevcik equation (Eq. 
1),  
I𝑝 = (2.69 ×  10
5)𝑛
3
2𝑣
1
2 𝐷
1
2 𝐶𝐴     (1) 
where n is the number of electrons transferred by the Fe3+/Fe2+ redox couple (n=1), v is the 
scan rate (v =50 mV/s), D is the diffusion coefficient (D = 7.20  10-6 cm2/s), and C is the 
analyte concentration (C = 5 mM).  An electroactive surface area of this value results in 
approximate 0.9% active sites (i.e., the surface area where heterogeneous charge transport 
occurs; active site is the ratio between electroactive surface area and geometric area) for the 
Fe3+/Fe2+ redox couple redox couple estimated during ferricyanide CV at a scan rate of 50 
mV/s.  Such values are greater than previous reports which demonstrate is greater than previous 
reports of 0.4% active sites.47 Thus, the porous nature of the VANTA IDEs significantly raises 
the electroactive surface area above a conventional solid or planar IDE sensor48 and provides 
more carbon-carbon defects or active sites than conventional CNT electrodes.49,50 
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To further demonstrate the impedimetric response of the VANTA IDEs, non-faradic 
impedance spectroscopy measurements were conducted in the frequency range from 0.1 Hz to 
1 MHz using increased concentrations of KCl (from 1.0 µM to 1.0 M KCl) (Figure 4.2c-f).The 
sensing mechanism is based on the disturbance of charge transfer dynamics between two sides 
of fingers.51 As the variation in the concentration of test samples caused a change in the number 
of ions in the electrolyte, the ion concertation in the IDE-electrolyte interface led to the 
decrease in the impedance response.51  Rs (solution resistance, roughly the diameter of the 
semicircle portion shown in 2 c & e) showed correlated changes within 10 µM and 1 mM, 
while the phase change is sensitive with 10 µM and 10 mM. Compared to previously reported 
2D CNT IDE, this sensing platform presents higher change in phase angle along with the 
change of KCl concentrations and wider sensing range; calculated double layer capacitance 
change was sensitive between 10 µM and 1 mM that was superior in sensitivity than reported 
2D CNT material as well.48 Several equivalent circuits have been built to model this behavior 
of impedimetric sensor in aqueous solution,39,40,52,53 and here the circuit decribded in Figure 
4.2f was utilized due to its simplicity and fit to our result. In this model, there are three main 
components the double layer capacitance Cdl, the solution electrolyte resistance Rs, and the 
solution dielectric capacitance Cde. Using this circuit model, Bode plots in Figure 4.2d that 
presents impedance change along with the change of frequency can be better explained. Within 
the lower frequency region, the current cannot pass through the double layer, making the 
parallel Cde inactive, thus Cdl dominate this the impedance reading. Physically speaking, the 
phenomena occurring in the neighborhood of the electrodes were measured in this region and 
surface related processes influence this capacitance.40 Consequently, the decrease of KCl 
concentration shows a negative trend of impedance measurement and shortened dominated 
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region by Cdl as result of fewer ions surrounded in this local environment. 
54 Then within the 
intermediate range, Rs governs the signal from the conduction of ions in the solution, and 
roughly a decreasing impedance reading from 10-5 to 10-1 M KCl can be observed 
corresponding to previous work by Hardeman et al.55 and Zou et al.40, who validated the 
conductivity of the solution is a determinant factor in constraining the signal of the sensor in 
this range.55 Along with the increase of frequency to much higher state, the current passes 
through Cde instead of Rs, resulting in Cde determined total impedance reading. Previous result 
might omit his range due to insensitivities to solution conductivity, but in this result, a clearly 
shortened high frequency region can be recognized due to the increase of KCl concentration.  
 
Figure 4.2. Electrochemical characterization of VANTA IDEs. (a) CV measurements at 
different scan rates (5, 10, 25, 50, and 100 mV/s). (b) Current density vs. scan rate1/2. (c) EIS 
measurements acquired in KCl solution with various concentration (10-6 M, 10-5 M, 10-4 M, 
10-3 M, 10-2 M, 10-1 M, and 1 M). (d) Phase change at 100 kHz and Rct measurements from 
(c). 
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FITC Fluorescence tagged secondary Abs were applied in this characterization to 
prove the successful Abs loading onto the electrode surface as done. In Figure 4.3a below, 
left image shows a positive fluorescence emission (the electrode finger was lighted up from 
the primary Abs bonded with the secondary fluorescence tagged Abs). It has to be noted that 
the maximum and minimum intensities in each image were used for normalization purpose. 
In the right image (Figure 4.3b), with the absence of the primary Ab, the fluorescence 
emission areas were flipped and the IDE fingers were seen as dark, that was due to the 
secondary Ab couldn’t attach to the electrode surface. 
 
Figure 4.3. VANTA IDE was functionalized with (a, positive control) and without (b, negative 
control) IFN-gamma Ab and blocked with 2% BSA. Next, 10 µL of 1:100 dilution of anti-
mouse IgG-FITC Ab produced in goat were placed on positive and negative controlled IDEs 
respectively and incubated for 1 hr. Fluorescence was ON from the positive controlled sample, 
indicating successful Ab loading onto the surface. 
 
With the confirmation of surface chemistry and Ab attachment from figure 3, 
optimum Ab loading on to the electrode surface was then studied based on the sensing of IL-
10 in PBS.  1:100 ratio and 1:50 ratio diluted IL-10 Abs were utilized following the protocol 
in Functionalization Chemistry section. Higher concentration of IL-10 Abs (1:50 dilution) 
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led to a wider sensing range (0.1 -100 pg/ml), while 1:100 dilution resulted in a sensing range 
of 0.1 to 50 pg/ml. Thus 1:50 dilution was selected to ensure better sensing range and 
sensitivity.  
Functionalized VANTA  IDE electrodes were tested in both ideal PBS buffer as well 
as in diluted cattle implant serum as well. Figure 4.4 shows the process of acquiring minced 
implant from cattle, after centrifuging which, the acquired supernatant was diluted 1000 
times and utilized in the sensing process. Selected Ab concentration (1:50 ratio) was applied 
into functionalized, and the resultant electrodes were tested three times in PBS buffer and 
diluted implant serum to show stability and repeatability.  Sensing IFN- (Figure 4.4 a & b) 
in PBS buffer presented a detection range of 0.1 -100 pg/ml with a detection limit of 0.054 
pg/ml (y = 31.177x + 79.987 and R² = 0.9401). While sensing in the cattle serum results in a 
sensing of 0.1 to 30 pg/ml and a detection limit of 0.077 pg/ml (y = 8.5558x + 13.035R² = 
0.9567). All sensing curves presented a large signal drop after the saturation point, which can 
be explained by the post-zone pheneomena.56 The precipitated Ab-Ag complex on the 
electrode surface can diassociate and become soluble into the solution when excess amount 
of Ags and electrolytes present. 56 
Following the same biofunctionalization protocol and tests, the detection of IFN- 
was studied in Figure 4.4 (c & d).From the sensing result of IL-10, Abs and Ags binding 
seemed to have higher variations in PBS buffer along with higher signal change output.  This 
can be inferred from the sensing range in PBS buffer that was calculated to be 0.1 to 50 
pg/ml with detection limit of 0.099 pg/ml (y = 28.03x + 60.292 (x= log (Concentration of 
IFN-) with R² = 0.9691). Compared to it, the sensing in cattle serum had a lowered but 
wider sensing range due impurities and interference species in the solution.  This complicity 
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might hindered the binding between Abs and Ags within the matrix, and the linear detection 
region covered 50-1000 pg/ml with a detection limit of 95.87 pg/ml (y = 0.027x + 2.3515 
with R² = 0.9724). 
 
Figure 4.4 (a & b) Sensing in PBS buffer with added concentrations of IFN- (0.1, 1, 10, 50, 
100, 200, 500 and 1000 pg/ml); (b) Sensing in diluted cattle implant supernatant with added 
concentrations of IFN- ( 0.1, 1, 10, 50, 100, 500, 1000, 5000,10000 and 15000 pg/ml). 
(c & d) Sensing was repeated three times in PBS buffer with increased concentrations of IL-
10 (0.1, 1, 10, 50,100, 200, 500 and 1500 pg/ml)  (d) Functionalized VANTA IDE from (c) 
was tested in 1:1000 ratio diluted cattle implant serum to evaluate its stability. Spiked 
concentrations of IL-10 were 0.1, 1,10,30,50,100,200 and 500 pg/ml.  
 
Finally, to evaluate the stability of this proposed sensing platform, the functionalized 
electrodes with IL-10 Abs and IFN- Abs were tested with increased concentrations of IL-6 
(1 pg/ml, 10 pg/ml and 100 pg/ml), BSA (0.5%, 1% and 2%), and increased incubation time 
in diluted cattle implant (5 mins, 30 mins and 60 mins). Funtionalized IDEs with IFN- Abs 
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were also tested with increased concentrations of IL-10 to eliminate the signal from cross 
reactivity. The results plotted in Figure 4.5 below indicated minimal and negligible 
percentage of Rct change compared to the baseline reading. The result indicated there was no 
non-specific bindings between the area that was not covered by Abs and interferences, thus 
this sensor is deemed stable and robust within complicated biological environment.   
 
Figure 4.5 Interference test. VANTA IDE was functionalized with IL-10 Abs and tested with 
the presence of IL-6 (1pg/ml, 10 pg/ml and 100 pg/ml), BSA (0.5%, 1% and 2%) and 
increased incubation time (5 mins, 30 mins and 60 mins). The representative sensing points 
of IL-10 (1, 10 and 100 pg/ml) are also in display in comparison with the interference 
measurements. 
 
4.5 Conclusion and Discussions 
In conclusion, the presented sensing platform is the first use of VANTA IDEs for 
electrochemical biosensing of bovine IL-10 and IFN-. CNT template microfabrication 
technique was used to fabricate carbon-infiltrate multiwalled CNT scaffolds composed of 
highly ordered and aligned CNT forest with desired VANTA IDE pattern and significantly 
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increased surface area.41 Integrated with the application of post O2 etching, the surface of the 
electrode presented carboxylic group as well as hydrophilic feature, which was well suited 
for biofuncionalization and edc/nhs chemistry.57 Both biomarkers are significant early stage 
indicators of Johne’s disease. The resulting sensing range in diluted cattle implant 
supernatant covered 50-1000 pg/ml for IFN-  with a theoretical detection limit of 95.87 
pg/ml; while for IL-10, the sensing range included  0.1 to 30 pg/ml and a detection limit of 
0.077 pg/ml. 
 Furthermore, this biosensor presented convincing stability and robustness in different 
biological environment and long sensing time from testing multiple target concentrations, 
which demonstrates the potential in future rapid (<35 minutes) and POC application. Without 
sample enrichment or skilled personal to conduct the sensing, it is an appealing alternative to 
conventionally utilized lab technique, which are time consuming, expensive and labor 
intensive. Moreover, this resultant VANTA sensing platform can overcome the challenges 
related with fluorescence/optical based sensors that require complex equipment/processes 
(e.g., fluorescence microscopes, pre-labeling steps), and does not suffer from problem related 
to stability and photobleaching of fluorophores.  Consequently, it  can be impeded by turbid, 
optically dense or autofluorescent biological samples.58 The fabrication protocol and material 
characterization results for 3D VANTA IDEs developed herein could be applied to emerging 
fields that have incorporated CNTs into numerous electrochemical applications including 
sensors, fuel cells, actuators, and energy harvesters.59–61  
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CHAPTER 5.    CONCLUSION 
In this dissertation, sensing method of EIS and IDE array are integrated together, in 
conjunction with equivalent circuit, modification of surface chemistry and modeling, to 
develop rapid (<35 mins) and sensitive biosensor for several biomarkers such as CIP2A, IL-
10, IFN-. Without sample enrichment or skilled personal to conduct the sensing, it is an 
appealing alternative to conventionally utilized lab technique, which are time consuming and 
labor intensive. Furthermore, electrochemical devices can circumvent the challenges 
associated with fluorescence/optical based sensors that require complex equipment/processes 
(e.g., fluorescence microscopes, pre-labeling steps) and that can be impeded by turbid, 
optically dense or autofluorescent biological samples. All of the tests toward EIS and IDE 
based biosensors help to establish the feasibility of utilizing them with POC in a doctor’s 
office or in a farm for disease diagnosis purpose. The material related study in this 
dissertation could also be applied to emerging fields that have incorporated CNTs into 
numerous electrochemical applications including sensors, fuel cells, actuators, and energy 
harvesters. 
 
 
